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II. INTRODUCTION 
1. BACKGROUND - MARINE COMPOUNDS IN CANCER THERAPY 
In the past decades, the interest in compounds from marine origins for cancer 
therapy has reached a so far unknown intensity. With new and safer scuba-
diving techniques, ocean regions down to a depth of 200 m became accessible 
and since the mid-1960s, approx. 10,000 substances have been isolated from 
marine microorganisms, seaweeds, sponges, soft corals and marine 
invertebrates. The enormous diversity of organisms in the sea is mirrored in 
these structures which also display an extreme variability [1]. Most possess 
bioactivity and, most likely, represent a chemical defence for the soft-bodied 
animals lacking a physical barrier [2]. Recent studies have suggested that some 
of the compounds are not synthesised by the organisms themselves but are 
taken up along with the consumed food or are produced by symbiotic bacteria 
[3;4]. 
 
Natural products and their derivatives play a fundamental role in cancer 
chemotherapy. Over 60 % of approved anticancer drugs are obtained from 
natural sources. However, in the period of 1981 to 2002, all new approved 
drugs were isolated from plants or microorganisms (Table 1). So far, no marine 
natural anticancer agent has been accepted to clinical use although several are 
in clinical trials (Table 2).  
 
The reason for this lies in part in the difficulties to provide sufficient material for 
preclinical and clinical trials. Often, the collection of organisms is hampered by 
unfavourable circumstances (adverse currents, sharks, etc.). Besides that, the 
concentration of the compounds is frequently so low that large quantities of the 
animals have to be harvested in order to achieve sufficient material. The 
ecological system, however, is heavily affected by these large intrusions into a 
previously unharmed environment. Scientists as well as pharmaceutical 
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companies search intensely for solutions to this problem. Chemical synthesis or 
mariculture (growing of marine organisms in controlled conditions) of the 
organisms might provide an approach but the structural complexity of numerous 
compounds complicates a synthesis. Moreover, the culture techniques for 
marine organisms have been improved over the last years but the specific 
requirements for many species are not easy to meet. In those cases, where a 
symbiotic metabolite producer is known, cultivation of these organisms has 
been attempted but often the microorganisms live as obligate symbionts and 
cannot be grown outside their host.  
Table 1: Chemotherapeutic agents introduced from 1981 – 2002 (adopted from [5]) 
 
Drug name Year of introduction 
Aclarubicin 1981 
Arglabin 1999 
BEC 1989 
Masoprocol 1992 
Paclitaxel 1993 
Pentostatin 1992 
Peplomycin 1981 
Solamargine 1987 
 
In spite of all obstacles, the results reached so far are very promising. In the 
development for new and highly active compounds, the marine products might 
play a significant role in that they can serve as templates for combinatorial 
chemistry coupled with high-throughput screening to identify new drug 
candidates [2;6]. 
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Table 2: Current Marine Organism-Derived Anticancer Drugs in Development (adopted 
from [1]) 
 
Drug name Source Organism (type) Development Stage 
Aplidine Aplidium albicans (tunicate) Phase II 
Bryostatin 1 Bugula neritina (bryozoan) Phase I, II 
Dolastatin 10 Dolabella auricularia (mollusk) Phase I, II 
Ecteinascidin 743 Ecteinascidia turbinata 
(tunicate) 
Awaiting approval of the 
EMEA 
Kahalahide F Elysia rubefescens (mollusk) Phase II 
Squalamine Squalus acanthias (dogfish 
shark) 
Phase II 
2. THE FAMILY OF CEPHALOSTATINS 
The cephalostatins isolated from the marine organism Cephalodiscus gilchristi 
Ridewood (see 2.1) belong to the most cytotoxic marine natural products ever 
tested by the National Cancer Institute/USA. Up to now, 19 derivatives could be 
characterised all of which show the same unique cytotoxicity profile in the NCI-
60 panel (see Figure 1). This panel displays the growth inhibitory potency of 
substances against 60 cancer cell lines of diverse origins [7;8]. All 
cephalostatins share this fingerprint which does not show significant 
correlations to any other compound neither of the standard agent database nor 
of the complete NCI compound database suggesting that the cephalostatins 
might employ novel signal transduction pathways [9].  
4 II Introduction  
Leukemia
Non-Small Cell Lung
Small Cell Lung
Colon
Central Nervous System
Melanoma
Ovarian
Renal
Prostata
Breast
GI50
-3 -2-1 0  1  2  3
Cell line
 
Figure 1: Fingerprint of cytotoxic profile of cephalostatin 1 evaluated by the NCI-60 
screen (September 2003). 
GI , 50 % growth inhibition. The zero value represents the mean of all cell lines tested. The 
bars indicate the deviation of the mean data obtained from the individual cell line from the 
overall mean and marks the sensitivity of the cell lines for cephalostatin 1 (negative bars, less 
sensitive; positive bars, more sensitive). 
50
Although the cytotoxicity profile of the cephalostatins does not differ, their 
potency varies depending on the chemical composition. Cephalostatin 1 (see 
) proved to be the most potent form in the NCI-60 panel [10]. 
Cephalostatins 2-4 [11], cephalostatin 10 – 11 [12], cephalostatin 16 – 17 [13], 
however, show dose dependencies comparable to cephalostatin 1. These 
structures differ in the right side moiety or the middle part of the molecule which 
seems not to interfere with the biological activity. In contrast, modifications in 
the left side unit decrease the potency as displayed by cephalostatin 5 – 9 
[14;15], cephalostatin 12 – 15 [16;17] and cephalostatins 18-19 [18]. 
Figure 2
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Figure 2: Chemical structure of cephalostatin 1. 
 
2.1 CEPHALODISCUS GILCHRISTI RIDEWOOD 
The marine worm Cephalodiscus gilchristi Ridewood (family Cephalodiscidae) 
(Figure 3) from which the cephalostatins were isolated belongs to the class of 
Pterobranchia (phylum Hemichordata). Pterobranchs are sessile colonial 
organisms living in tubes (coenecia) composed of a gelatinoid substance which 
is secreted by glands in the anterior part of their body. The colonies often 
contain several hundred individuals (zooids).  
 
Their body is segmented into three parts, the prosoma, the mesosoma and the 
metasoma. The upper body segment, the prosoma, is modified to a cephalic 
shield on which the zooid is able to crawl on the inner and outer side of the 
coenecium (Figure 4). From the collar-like mesosoma, 4 – 10 arms, the 
lophophores, protrude dorsally carrying a double row of ciliated tentacles. A 
mucus net is formed among the tentacles in which planktonic particles are 
trapped. Cilia on the tentacles transport the mass towards the mouth on the 
ventral side of the animal. The sac-like metasoma contains the major part of the 
U-shaped digestive tract which is composed of a short pharynx and 
oesophagus  
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Figure 3: Cephalodiscus sp. (family Cephalodiscidae) [19]. 
Left panel, individual worms; right panel, colony in their coenecia.  
followed by a wide stomach. From the end of the stomach, the intestine 
proceeds after a loop dorsally towards the mesosoma. The mouth is located on 
the ventral side in the mesosoma, the anus sits directly opposite the mouth on 
the back. In Cephalodiscus sp., one pair of gill slits opens from the lateral sides 
of the pharynx to the outside. On the far end of the metasoma, the body 
extends into a contractile muscular stalk (stolo) of several body lengths 
depending on the state of contraction. Together with the prosoma, the animal 
can use the stolo as organ of locomotion [20;21].  
 
The animals are dioecious. In female zooids, a pair of ovaries is situated in the 
mesosoma. From there, two ducts lead to dorsal pores. Cephalodiscus sp. 
breeds two embryos which develop into a ciliated planula-shaped larva. 
Metamorphosis occurs after a short life in free suspension [22]. Although sexual 
reproduction is the normal method, pterobranchs are capable of asexual 
reproduction by budding. The buds develop out of the stalk and are released 
early in development. They form their own coenecium near the parent zooid 
thus giving rise to colonies. 
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Figure 4: Illustration of Cephalodiscus sp. (adapted from [20]) 
 
The zooids possess a single blood vessel in which the heart located dorsally in 
the metasoma pumps the blood to the lower part of the body and draws it 
ventrally to the top. The nervous system lies intraepithelially in the epidermis 
and forms a ganglion below the lophophore.  
2.2 BIOLOGICAL ACTIVITY OF CEPHALOSTATIN 1 
Cephalostatin 1 was tested extensively by the National Cancer Institute in order 
to assess the growth inhibitory effects. The values obtained from the assays 
yielded a mean GI50 concentration of approximately 1 nM in the 2-day NCI-60 
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screen [23]. Beyond the in vitro tests, cephalostatin 1 was tested on several 
xenografts such as melanoma, sarcoma, leukaemia and even on a human 
mammary carcinoma model. All these tumours were inhibited in vivo [24].  
3. AIM OF THE WORK 
The marine compound cephalostatin 1 displays a unique cytotoxicity profile in 
the NCI-60 screen demonstrating its potent cytostatic effect. However, the 
mode of action of cephalostatin 1 as cytotoxic agent has not been investigated 
yet. Therefore, the present study focuses on the signalling pathway involved in 
the apoptotic cell death induced by cephalostatin 1 in Jurkat leukaemia T cells. 
4. APOPTOSIS / PROGRAMMED CELL DEATH AND NECROSIS 
Apoptosis or programmed cell death is an essential physiological process 
governing development and homeostasis of multicellular organisms. The term 
“apoptosis“ was first coined by Kerr et al. in 1972 when he described a distinct 
form of cell death characterised by cell shrinkage, internucleosomal cleavage of 
chromatin, blebbing of the plasma membrane and finally fragmentation of the 
cell into apoptotic bodies. The apoptotic bodies are enclosed by an intact 
plasma membrane. On this way, leakage of cellular material into the 
surrounding tissue and subsequent inflammation is prevented [25]. The vesicles 
shed by apoptotic cells are phagocytosed by adjoining cells and macrophages. 
Apoptotic bodies are recognised, among others, by phosphatidylserine 
molecules present on the surface after their externalisation in the course of the 
apoptotic process [26;27]. The biochemical features of apoptosis follow a 
genetically controlled program that is evolutionarily conserved in almost all 
multicellular organisms. Studies of the molecular mechanisms in Caenorhabditis 
elegans provided an excellent background for the elucidation of the mammalian 
apoptosis pathways (see 5) [28].  
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In contrast to apoptosis, another cell death termed necrosis occurs after injuries 
or excessive contact with cytotoxic agents and typically induces inflammation 
[25]. Necrosis does not follow a designated molecular pathway but is defined by 
cellular swelling followed by a burst of the plasma membrane spilling the cellular 
content into the surrounding tissue. Thus, apoptosis and necrosis were initially 
regarded as two distinct forms of cell death.  
 
However, not all apoptotic cells are engulfed by phagocytes. These 
unrecognised apoptotic particles may undergo a secondary necrosis [29] (see 
). This finding led to the recent perception that necrosis is not so much 
a death pathway per se, distinguishable from apoptosis, but the process 
occurring after the cell has died [30;31]. Beyond that, recent studies in knockout 
mice revealed the potential conversion of an apoptotic process to necrotic cell 
death by silencing the mediators of the apoptotic cascade [32]. This suggests 
that a clear separation between the two forms of cell death might not be justified 
since an obvious crosstalk between the apoptotic and necrotic pathway exists. 
Figure 5
 
During the entire course of embryogenesis, apoptotic processes govern the 
correct formation and development of tissues and organs. Tissue homeostasis 
is reached by a delicate balance between cell proliferation and apoptosis. 
Thereby, especially old, mutated or otherwise damaged cells are removed [33]. 
Furthermore, homeostasis of the immune system is a field where apoptosis 
plays a particularly important role. The proliferation of T and B lymphocytes is 
regulated by means of positive selection in order to ensure that only those cells 
with correctly rearranged antigen receptors stay alive [34]. Negative selection 
achieves the apoptotic death of self-reactive immune cells [35].  
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Figure 5: Distinction between apoptosis and necrosis (adapted from [36]). 
Apoptosis denotes the organised fragmentation of the cell into apoptotic bodies without spillage 
of cellular contents into the surrounding tissue (c, condensation and blebbing; d, fragmentation 
into apoptotic bodies with intact membranes; e, phagocytosis of apoptotic bodies by 
phagocytes). In contrast, in necrosis or accidental cell death, the cell is ruptured and leakage of 
cell material induces inflammation (a, cell swelling; b, disintegration of the cell). When apoptotic 
bodies are not phagocytosed by macrophages or adjacent cells, a secondary necrosis might 
develop. 
5. SIGNAL TRANSDUCTION IN APOPTOSIS 
In apoptosis, the cell is subject to biochemical alterations such as degradation 
of a variety of proteins, condensation of chromatin, internucleosomal cleavage 
of DNA and finally fragmentation of the cell into apoptotic bodies. These 
processes are executed and mediated by a complex molecular machinery 
including death-specific enzymes and regulatory molecules. Most prominent in 
this array are the caspases – a family of proteases which is divided into initiator 
and effector caspases (see under 5.1). Once the cell receives an apoptosis-
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inducing signal, the caspases are activated in a cascade leading eventually to 
the demise of the cell. Currently, three different apoptotic pathways have been 
proposed depending on the death signal: the extrinsic or receptor-mediated 
pathway (5.2), the intrinsic or mitochondrial pathway (5.3) and the ER-mediated 
pathway (5.4). Of course, these signalling pathways do not always proceed 
independently of each other since interaction at diverse stages has become 
obvious in numerous models.  
5.1 CASPASES 
The family of cysteine-dependent caspases plays a pivotal role in the regulation 
of apoptosis. To date, the family comprises 14 members which all display the 
unique specificity for substrate cleavage after an aspartate residue. Only one 
other mammalian protease, the T lymphocyte serine protease granzyme B, 
shares this feature [37]. Apart from the function of caspases in apoptosis, some 
members of the family are involved in inflammation by their cytokine processing 
ability. 
 
Caspases are synthesised as inactive zymogens which share a similar structure 
(Figure 6). The pro-caspases are composed of a N-terminal prodomain followed 
by a large (~ 20 kDa) and a small subunit (~ 10 kDa). The large subunit 
contains the catalytic cysteine residue within a conserved QACXG motif. For 
processing, the zymogen is first cleaved between the large and the small 
subunit. Subsequently, the prodomain is removed. An active heterotetrameric 
caspase is formed by self-association of two processed zymogens and consists 
of two large and two small subunits. Each heterodimer contains an active site 
formed by residues of both the large and small subunit [38;39].  
 
Caspases are classified as either initiator caspases which are activated first in 
the cascade (caspase-1, -2, -4, -5, -8, -9, -10 and -12) or executor caspases 
which are activated by initiator caspases (-3, -6, -7 and -14) [40]. Initiator 
caspases are characterised by a long prodomain which contains special 
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structural motifs such as DED (death effector domain; caspase-8 and -10) or 
CARD (caspase recruitment domain; caspase-4, -5 and -9). These motifs serve 
as binding sites to adaptor molecules such as FADD (see 5.2) or Apaf-1 (see 
5.3) which are crucial for the activation of initiator caspases in that they connect 
the pro-caspase to apoptotic sensors (death receptors or mitochondria) and 
bring the two zymogens into close proximity enabling transactivation [41]. 
 
H2N COOH
H2N COOHCARD
active caspase
pro-caspase-8, -10 (initiator)
pro-caspase-9, -12 (initiator)
pro-caspase-3, -6, -7 (effector)
H2N COOHDED DED
QACxG
p10
Lg
Lg
Lg
Sm
Sm
Sm
p20 active sites
 
Figure 6: Schematic illustration of the structure of zymogens and active caspases. 
Pro-caspase-8 and -10 carry two repeats of the DED in their long prodomain (blue) whereas a 
CARD domain is present in the prodomain of caspase-9 and -12. All effector caspases have 
short prodomains. The active caspase is composed of two small (Sm) and two large subunits 
(LG) and contains two active sites. The caspase cleavage motif including the catalytic cysteine 
(QACxG) is located in the large subunit. 
Active effector caspases are responsible for the regulated disassembly of the 
apoptotic cell by cleaving the so-called death substrates. The range of these 
substrates is vast and includes inactivation of survival mechanisms as well as 
degradation of structural proteins. The latter is evident e.g. in an extensive 
actin, fodrin and lamin cleavage provoking dissolution of the nucleus and cell 
shrinkage [42]. Cleavage of the DNA repair enzyme PARP (poly (ADP-ribose) 
polymerase) as well as the destruction of ICAD (inhibitor of caspase-activated 
DNase) leading to functional CAD / DFF (caspase-activated DNase / DNA 
fragmentation factor) aids in DNA fragmentation [39]. Beyond the repair 
enzymes, cleavage of proteins involved in cell cycle regulation results in a halt 
of proliferative activity [43]. An amplification of the apoptotic process is achieved 
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by activation of further caspases. This area also implies the inactivation of anti-
apoptotic proteins such as Bcl-2 and Bcl-xL [44;45]. 
 
Given the destructive potential of active caspases for cellular fate, various 
mechanisms have developed for tightly controlling activation of the cell death 
mediators. These regulations include mechanisms that prevent caspase 
activation as well as the inhibition of active caspases. The former is obtained by 
anti-apoptotic proteins of the Bcl-2 family (see 5.3.1). Caspase inhibitors were 
first identified in cowpox viruses and baculoviruses which encode three classes 
of inhibitor proteins: CrmA (cytokine responsive modifier A), p35 and IAPs 
(inhibitor of apoptosis proteins) [46]. CrmA belongs to the serpin family and 
inhibits caspase-1 and -8 while p35 is a broad spectrum caspase inhibitor [47]. 
Both proteins are pseudosubstrate inhibitors acting by stably binding to the 
active site of their target caspase [48]. No mammalian homologues of CrmA or 
p35 have yet been identified. In contrast, several homologues of IAPs inhibit 
caspase-3, -7 and -9 in mammalian cells. Two mechanisms are described for 
IAP inhibition. First, they bind directly to the active site of caspase-3 and 
caspase-7. In addition to blocking of the active site, further inhibition of 
caspase-9 is achieved by direct interaction of IAPs with pro-caspase-9 and 
competing for Apaf-1 binding sites thereby preventing the processing of the 
zymogen form [49;50] (see also 5.3.2). 
5.2 EXTRINSIC PATHWAY / DEATH RECEPTOR PATHWAY 
The extrinsic pathway integrates death signals via cell surface receptors. Death 
receptors belong to the TNF (tumor necrosis factor) receptor superfamily  
characterised by 2 – 5 extracellular cysteine-rich domains. In addition, death 
receptors contain a homologous cytoplasmic sequence referred to as death 
domain (DD). In mammals, several members of the superfamily are known such 
as TNF-R1, DR3, DR6, TRAIL-R1, TRAIL-R2 and the most extensively studied 
CD95 which plays a fundamental role in maintainance of a functional immune 
system [51]. Among these, some receptors, the so-called decoy receptors, 
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display truncated DDs suggesting an inhibition of transmission of the death 
signal to the apoptotic machinery [52].  
 
Ligands specific for the death receptors are members of the TNF gene 
superfamily. By binding of the homotrimeric molecules to their receptor, three 
death receptors are brought close allowing a clustering of the intracellular DD. 
Since the receptor has no enzymatic activity, the activation of pro-caspases 
requires cytoplasmic adaptor molecules. In the case of CD95, this role is 
appointed to FADD (Fas-associated death domain) which is recruited via its 
own DD to the receptor triad. FADD contains another domain termed DED 
(death effector domain) that binds to the DED repeated in tandem in the  
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Figure 7: Components of the receptor-mediated apoptotic pathway. 
On binding of CD95 ligand, CD95 trimerises and recruits FADD on its cytosolic domains via 
interaction with the death domain (DD). FADD binds pro-caspase-8 to its death effector domain 
(DED) completing the death-inducing signalling complex (DISC). Pro-caspase-8 is activated in 
the DISC through autolytic cleavage.  
prodomain of caspase-8 (Figure 6). The complex composed of DD, FADD and 
two pro-caspase-8 molecules is referred to as DISC (death inducing signalling 
complex). In the DISC, pro-caspase-8 is autolytically cleaved and activated to 
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induce downstream effector caspases like caspase-3 and caspase-7. Other 
receptors employ mainly the same mode of caspase activation but include 
additional adaptor molecules in the signal transduction (e.g. TRADD – TNF 
receptor-associated death domain) [53;54].  
5.3 INTRINSIC PATHWAY / MITOCHONDRIAL PATHWAY 
Awareness of the importance of mitochondrial signals in apoptosis has 
increased tremendously in the past years. Once the basic principles were 
elucidated, increasing numbers of regulating mechanisms have been revealed.  
 
Being the “powerhouse” of the cell, mitochondria fulfil vital functions in 
metabolism. Two membranes surround the two compartments of mitochondria: 
the matrix separated from the outside by the inner mitochondrial membrane 
(IMM) and the intermembrane space between the IMM and the outer 
mitochondrial membrane (OMM). The IMM contains the protein complexes of 
the electron transport chain which are important for the formation and 
maintenance of the mitochondrial membrane potential. Some proteins involved 
in the transport of electrons across the respiratory chain such as cytochrome c 
are located in the intermembrane space. The electrochemical gradient is 
required for ATP synthesis by the ATP synthase also present in the IMM. The 
transport of ADP molecules across the IMM into the matrix is performed by the 
ANT (adenine nucleotide transporter). The OMM also comprises a transport 
protein involved in respiration, the so-called VDAC (voltage-dependent anion 
channel) [55].  
 
Beyond the function in cell metabolism, mitochondria play an essential role in 
stress-induced apoptosis. Often, chemotherapeutic agents, UV radiation or free 
radicals induce mitochondrial apoptosis characterised by a dissipation of the 
electrochemical gradient and the release of apoptogenic factors. The latter are 
harboured in the intermembrane space and include cytochrome c, AIF 
(apoptosis-inducing factor), EndoG (endonuclease G) and Smac / DIABLO 
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(second mitochondria-derived activator of caspases / direkt IAP binding protein 
with a low isoelectric point) [56]. Once an apoptotic signal has been transduced 
to the mitochondria, the apoptogenic factors are released into the cytosol. AIF 
and EndoG translocate into the nucleus inducing chromatin condensation and 
DNA fragmentation. These processes proceed independently of ATP and 
caspase activity. The function of Smac consists in the inhibition of IAPs (see 
5.3.2).  
 
Unlike the other factors that are not or only indirectly involved in caspase 
activation, cytochrome c is of utmost importance for the activation of caspase-9, 
the initiator caspase in the mitochondrial pathway. In the presence of 
cytochrome c, a cytosolic factor referred to as Apaf-1 (apoptosis protein-
activating factor 1) undergoes a conformational change upon hydrolysis of 
dATP / ATP to dADP / ADP resulting in oligomerisation of Apaf-1. Apaf-1 carries 
a CARD domain by which a pro-caspase-9 can be recruited in a 1 : 1 ratio 
leading to the assembly of an apoptosome. In this complex, pro-caspase-9 is 
able to perform self-cleavage analogue to the activation of caspase-8 in the 
DISC. After activation, caspase-9 is able to initiate the caspase cascade [57].  
 
The mode of release of the apoptogenic factors from the intermembrane space 
is still subject of investigations. It was proposed to occur through a pore 
complex called the permeability transition pore (PTP) at the contact sites 
between the two mitochondrial membranes. The PTP is mainly composed of the 
ANT in the inner and the VDAC in the outer membrane. Opening of the PTP 
results in dissipation of the membrane potential leading to the observed swelling 
of the mitochondrial matrix. Beyond the PTP, pro-apoptotic members of the Bcl-
2 family such as Bax and Bak (see 5.3.1) have the ability to directly form pores 
in the OMM thus inducing release of the apoptogenic proteins. Anti-apoptotic 
Bcl-2 family proteins play important roles in maintaining the integrity of the 
mitochondrial membranes by several mechanisms (see 5.3.1) [58]. 
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Figure 8: Schematic illustration of the mitochondria-mediated apoptotic pathway.  
Cytochrome c (C) is released into the cytosol where it interacts with Apaf-1, ATP and pro-
caspase-9 resulting in apoptosome formation. Hence, caspase-9 is activated. IAP (inhibitor of 
apoptosis protein) is able to bind to the active site of active caspase-9 leading to inhibition of 
apoptosis. Smac (S) acts as inhibitor of IAPs in that it competes with caspase-9 for the IAP 
binding site. AIF, once released, translocates into the nucleus and mediates DNA 
fragmentation. The anti-apoptotic proteins Bcl-2 and Bcl-x  inhibit the release of apoptogenic 
factors from the intermembrane space. 
L
5.3.1 The Bcl-2 Family 
Members of the Bcl-2 family, an evolutionarily conserved group of proteins, are 
important regulators of the apoptotic processes converging on the mitochondria 
as well as the endoplasmatic reticulum (ER). Bcl-2, the first recognised member 
of the family, was found in B-cell lymphoma hence the name Bcl. The proteins 
are divided into three subgroups determined by their structure and function: 
 
1. the anti-apoptotic fraction including Bcl-2, Bcl-xL, Bcl-w, A1, Mcl-1 and Boo  
2. the pro-apoptotic Bax / Bak-like group encompassing Bax, Bok, Bcl-xs, Bak 
and Bcl-GL 
3. the pro-apoptotic BH3-only proteins comprising Bad, Bik, Bid, Hrk, Bim, 
Bmf, Noxa and Puma 
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The structure of the Bcl-2 family proteins exhibits certain regions of homology 
referred to as BH1 – 4 (Bcl-2 homology) (Figure 9). Depending on the group, 
the proteins share either the BH domains 1 – 4 (anti-apoptotic), domains B1 – 
B3 (Bax / Bak-like) or only the BH3 domain (BH3-only). Most Bcl-2 proteins 
contain an N-terminal transmembrane region mediating their localisation to 
membranes of mitochondria, ER and nucleus [59].  
 
Figure 9: Schematic illustration of representative members of the Bcl-2 family 
subgroups.  
embrane region (TM) while most Bax-like proteins lack the BH4 domain. Some 
The BH3-only proteins seem to act upstream in the apoptotic cascade and 
ue to the fundamental role of BH3-only proteins in apoptosis promotion, 
BH1 BH2BH3BH4 TM
BH1 BH2BH3 TM
BH3
BH3 TM
Bcl-2
Bax
Bid
Bik }BH3-only
 
Anti-apoptotic proteins such as Bcl-2 contain four Bcl-2 homology (BH) domains and an N-
terminal transm
BH3-only proteins may contain the TM (adapted from [60]). 
promote apoptosis by interaction with Bax / Bak-like proteins thereby inducing 
cytochrome c release (only Bid) or with anti-apoptotic Bcl-2 proteins thus 
inhibiting their protective role (all BH3-only members). Interaction between the 
different proteins occurs via docking of the amphiphatic α-helical BH3 domain of 
the BH3-only molecules into the hydrophobic groove composed of the BH1 – 
BH3 regions of the target protein. The BH3-only proteins are expressed in a 
cell-type specific manner and serve as sensors to diverse kinds of cellular 
stress.  
 
D
several mechanisms have emerged to tightly control the action of these 
mediators. Many are sequestered to cellular compartments other than the 
mitochondria and released only on apoptotic signaling (Bim, Bmf). Beyond that, 
dephosphorylation (Bad) as well as cleavage (Bid) is required for activation. Bid 
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is cleaved by active caspase-8 to a truncated form, tBid. tBid then translocates 
to the mitochondria and interacts with Bax and Bak resulting in conformational 
changes. The altered conformation of Bax / Bak allows insertion into the 
mitochondrial membrane and heterodimerisation provoking formation of pores 
and release of apoptogenic factors from the intermembrane space. Activation of 
Bax / Bak by tBid allows an amplification of the receptor-mediated apoptosis 
and indicates the intense crosstalk between the two pathways [56]. Another 
model for the induction of membrane permeability by Bax / Bak mentions the 
protein-protein interaction with ANT as well as VDAC in the mitochondrial 
membranes. On this way, Bax / Bak are suggested to induce formation of the 
PTP [61;62]. 
 
The mechanism by which anti-apoptotic proteins confer protection from 
5.3.2 Smac / DIABLO 
Smac is a constitutively expressed 21 kDa protein located in the mitochondrial 
mitochondrial damage includes two interaction sites. First, they bind to Bax / 
Bak-like proteins thus inhibiting conformational changes and insertion into the 
membrane. Second, they have been proposed to interact with pore-forming 
proteins in the membrane such as VDAC preventing channel formation [63]. 
Negative regulation of the anti-apoptotic proteins results from cleavage, 
hyperphosphorylation and interaction with BH3-only proteins [64].  
intermembrane space and composed of α-helical bundles. The structure of the 
active form is an arch-shaped dimer with the C-terminus located at the 
respective ends of the arch. The protein is nucleus encoded and carries a 
mitochondrial location sequence on the N-terminus. On entry into the 
mitochondrial intermembrane space, this sequence is removed. Like 
cytochrome c and AIF, Smac is released upon apoptotic signals into the cytosol 
where it prevents the inhibition of caspases by IAPs [65].  
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Smac can interact with all mammalian IAPs, but its highest affinity was 
determined for human XIAP (X-linked inhibitor of apoptosis). IAPs bear 1 – 3 
BIR domains (baculovirus IAP repeats) which are essential for their binding 
ability of caspase-3, -7 and -9. Caspase-3 and -7 are sequestered by the linker 
region between BIR1 and BIR2 while caspase-9 is bound by BIR3. Smac, 
however, is able to bind to BIR2 and BIR3 via its four N-terminal amino acids 
(Ala-Val-Pro-Ile) that became accessible after processing for mitochondrial 
entry thus competing for the caspase-9 binding site. The binding of caspase-3 
and caspase-7 is most probably hindered by steric reasons once Smac has 
bound to BIR2 [66]. 
 
The IAP-inhibitory function of Smac is well established in in vitro models. In 
vivo, though, it has been shown that Smac-/- mice develop normally without any 
apparent phenotypes [67]. In addition, a splice variant referred to as Smac-β 
lacking the mitochondrial localisation sequence and the IAP binding region 
exerts pro-apoptotic effects although the mechanism has not been elucidated 
yet [68]. Most likely, the IAP inhibition pathway contains redundant effectors and 
one of the four known XIAP binding proteins is probably able to compensate for 
the loss of Smac [69]. 
5.4 ER-MEDIATED PATHWAY 
The endoplasmic reticulum (ER) serves many vital functions as intracellular 
Ca2+ store and as site for protein folding and modification (e.g. glycosylation). 
Folding is carried out by chaperones such as BiP (binding protein). When the 
load of unfolded proteins rises above the capacity of the ER, a stress response 
named UPR (unfolded protein response) is triggered resulting in an 
upregulation of regulatory factors (e. g. chaperones) and a downregulation of 
protein synthesis. If these repair measures do not take hold, apoptosis is 
induced as final response [70;71]. Apoptosis induction triggered by ER signals 
involves several mechanisms beyond the caspase activation described below. 
Mechanisms include enhanced expression of the transcription factor CHOP / 
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GADD153 (C/EBP-homologous protein / growth arrest and DNA damage 
inducible protein 153) which triggers the transcription of apoptosis-relevant 
genes and JNK activation. 
 
IRE1a/IRE1b
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Figure 10: Schematic representation of the ER-mediated pathway (adapted from [72]).  
The unfolded protein response (UPR) triggers the dimerisation of IRE1 via BiP signalling. 
Subsequently, IRE1 is able to activate JNK through TRAF2 (TNF-receptor associated factor 2), 
caspase-12 or to initiate transcription of BiP and CHOP. In ER stress, the Ca  stores in the ER 
lumen is emptied into the cytosol resulting in activation of the Ca -dependent protease calpain. 
2+
2+
The regulation of ER-mediated apoptosis is very complex and involves several 
members of the Bcl-2 family as well as Ca2+ as major constituent of the signal 
transduction. When, upon an apoptotic signal or mediated by the UPR, the Ca2+ 
store is emptied into the cytosol it induces activation of calpains [73], Ca2+-
dependent proteases which are implicated either in activation of Bax (see 5.3.1) 
or of caspases. Also, it mediates Bad dephosphorylation and activation by 
induction of Ca2+–dependent calcineurin. In addition, through transport of Ca2+ 
from the ER into the mitochondria via close contacts of the membranes, the 
mitochondria are sensitised to the action of pro-apoptotic proteins thus leading 
to an enhanced release of cytochrome c. The Ca2+ concentration of the ER 
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lumen is very important in cellular sensitivity to apoptotic stimuli since a 
decreased [Ca2+]ER leads to resistance to ER-related apoptosis [74]. 
 
The ER-related apoptotic pathway employs two initiator caspases depending on 
the cell type. Caspase-12 was first detected in murine fibroblasts [75]. It is 
located exclusively on the cytoplasmic side of the ER membrane. Activation of 
caspase-12 is still not completely explained but seems to involve diverse 
mechanisms such as cleavage by calpain [76] or autolytic activation after 
recruitment to IRE1 / TRAF-2 (TNF receptor associated factor) [77]. In addition, 
caspase-7 was shown to translocate to the ER and activate caspase-12 [78]. 
Downstream of caspase-12, besides activation of effector caspases, a direct 
activation of caspase-9 by caspase-12 independently of cytochrome-c was 
shown by recent studies [79]. 
 
Another initiator caspase is an isoform of caspase-8, caspase-8L [80], which is 
peripherally associated with the ER membrane and is recruited to another ER 
surface protein called BAP31 (B-cell antigen receptor-associated protein) 
allowing self-activation. Apart from unleashing active caspases, ER stress 
signals attract Bax and Bak to the ER membrane which also induce Ca2+ 
release.  
 
Regulation proceeds by members of the Bcl-2 family. Beyond its localisation in 
the mitochondrial membrane, the anti-apoptotic protein Bcl-2 is also present at 
the ER. ER-based Bcl-2 maintains Ca2+ homeostasis and prevents caspase 
activation by interaction with BAP31 and pro-apoptotic Bax / Bak and Bik [81]. 
The latter is a BH3-only protein located mainly on the ER. It has been shown 
that the Bik : Bcl-2 ratio plays a crucial role in the induction of ER-related 
apoptosis. In addition to the crosstalk through Ca2+ transfer, a high Bik : Bcl-2 
ratio allows Bik to initiate crosstalk between ER and mitochondria by inducing 
Bax-dependent release of cytochrome c [82]. Furthermore, Bcl-xL is also 
present at ER membranes and serves anti-apoptotic functions. 
III.  MATERIALS AND METHODS 
1. MATERIALS AND SOLUTIONS 
All chemicals were purchased at Sigma-Aldrich (München, Germany) or Roth 
(Karlsruhe, Germany) unless stated otherwise.  
 
PBS       TBS-T    
NaCl  7.20 g     Tris-base   3.0 g 
Na2HPO4 1.48 g     NaCl  11.1 g 
KH2PO4 0.43 g     Tween-20   2 ml 
H2O  ad 1000 ml    H2O  ad 1000 ml 
2. CEPHALOSTATIN 1 
Cephalostatin 1, isolated as described in the following protocol, was kindly 
provided by Dr. G. R. Pettit (Cancer Research Institute, Arizona State 
University, Tempe, USA) [10].  
2.1 ISOLATION  
The Cephalodiscus gilchristi Ridewood specimens used for isolation of 
cephalostatin 1 were collected by scuba at a depth of 20 m in the Indian Ocean 
south-east of Africa. Extraction and isolation of cephalostatin 1 were performed 
as described by Pettit et al. [10].  
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3. CELL CULTURE 
3.1 CELL LINES 
The subclone J16 of the Jurkat cell line, derived from an acute lymphatic 
leukemia, was graciously provided by Dr. S. Eichhorst (Klinikum Großhadern, 
Munich, Germany). This subclone is particularly sensitive to CD95-induced 
apoptosis. Jurkat T cells transfected with vector control, bcl-2 or bcl-xL [83] as 
well as CD95 deficient cells [84] were kindly provided by Drs. P. Krammer and 
H. Walczak (DKFZ, Heidelberg, Germany). Jurkat cells carrying a vector 
control, wildtype bcl-2 or a bcl-2 mutant in which Ser69, Thr70 and Ser87 were 
changed to Ala were made available by Prof. S. Korsmeyer (Dana Farber 
Cancer Institute, Boston, USA [85]). 
 
All cells were cultured in RPMI 1640 (PAN Biotech, Aidenbach, Germany), 
supplemented with FCS gold (PAA Laboratories, Cölbe, Germany) and 
pyruvate, in a humidified atmosphere at 5 % CO2 and 37° C. For experiments, 
no passage higher than 20 was used. For transfected cells, in order to remove 
any cells having lost their plasmids, the selection antibiotic geneticin (G418, 
PAA Laboratories, Cölbe, Germany) at a final concentration of 1 mg/ml was 
added every fifth passage. Cells exposed to G418 were not used for 
experiments. 
3.2 CELL CULTURE TECHNIQUES 
3.2.1 Freezing and thawing 
For long-term storage, passages 1-10 were stored in liquid nitrogen while higher 
passages were kept at –80° C. Since ice crystals forming during the freezing 
process could rupture the cells, a special freezing medium was used. 
Cells were centrifuged at 360 x g, resuspended in freezing medium at a 
concentration of 5 x 105 (1.5 ml per cryovial) and frozen at –20° C for one day. 
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Afterwards, they were transferred to –80° C and, if desired, after another day to 
liquid nitrogen. 
 
Freezing medium  
RPMI 1640 70 % 
FCS gold 20 % 
DMSO 10 % 
 
The content of a cryovial was defrosted by gently dissolving in 30 ml prewarmed 
complete medium. The culture was left to grow for at least five days before any 
experiments. 
3.2.2 Determination of cell concentration 
Due to the fact that the genome of Jurkat cells is quite unstable and mutations 
occur frequently when cell density is too high, cultures must not be grown over 
1.5 x 106 cells / ml. For the determination of the cell concentration 1 ml of cell 
suspension was transferred to an Eppendorf tube, vortexed and analysed in a 
Coulter Counter (Coulter, Krefeld, Germany). The concentration required was 
achieved by dilution with prewarmed medium. 
3.2.3 Splitting and seeding 
Cells were split every two to three days and diluted to 1 x 105 / ml respectively  
8 x 104 / ml before weekends.  
For experiments, cells were seeded a day before stimulation. The cell 
suspension was centrifuged at 360 x g and resuspended in prewarmed 
medium. After determining the cell density, the appropriate concentration was 
adjusted by dilution in prewarmed medium. Table 3 shows the concentrations 
used in the following experiments. 
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Table 3: Experimental conditions. 
 
Experiment Concentration Plate Volume
Cytotoxicity test (MTT assay) (4.1) 9 x 105 /ml 96 well 100 µl 
Propidium iodide exclusion assay / 
quantification of apoptosis according to 
Nicoletti et al. [86] (4.2, 5.2) 
7 x 105 / ml 24 well 500 µl 
Staining by Annexin V (5.3) 7 x 105 / ml 24 well 1 ml 
Staining by JC-1 (5.4) / staining with 
Hoechst 33342 (6.2.1) 
7 x 105 / ml 24 well 1 ml 
Immunocytochemistry / transmission 
electron microscopy (6.3, 6.4) 
7 x 105 / ml 24 well 1 ml 
Caspase activity assay (7) 5 x 105 / ml 24 well 500 µl 
Western Blot analysis (8) 7 x 105 / ml 24 well 1 ml 
Comet assay (10) 6 x 105 / ml 24 well 1 ml 
4. CYTOTOXICITY ASSAYS 
4.1 MTT ASSAY 
The degree of cytotoxicity of a substance can be measured with a colorimetric 
assay using the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide). The assay is based on the reduction of MTT by enzymes 
of the mitochondrial electron transport assembly, which produces blue 
formazans. The reduction is proportional to the activity of the assembly and thus 
to the vitality of the cell. The absorption of the formazans can be measured at 
550 nm in a spectrophotometer [87].  
 
Protocol: 
Cells were seeded at a concentration of 9 x 105 / ml in a 96-well plate (100 µl 
per well) the day before stimulation. Stimulation was carried out with different 
concentrations of cephalostatin 1 (0.1 nM – 100 µM) for 24 h. 1 µl of DMSO was 
III Materials and Methods  27 
used as control for zero inhibition and etoposide was applied as positive control 
at a concentration of 25 µg / ml. After 24 h, 10 µl of MTT solution (stock 
solution: 5 mg/ml in PBS, sterile filtered and kept in aliquots at –20° C) were 
added to each well and incubated at 37° C for 60 minutes. After that, cells were 
lysed by adding 190 µl DMSO to each well and shaking the plates in the dark 
for another hour. Finally, the absorption of the solubilised formazan crystals was 
measured at 550 nm in an ELISA plate reader (SLT spectra, SLT 
Labinstruments, Crailsheim, Germany). 
4.2 PROPIDIUM IODIDE EXCLUSION ASSAY 
Propidium iodide (PI) is a fluorochrome which intercalates into the DNA. It 
absorbs light at 488 nm (maximum) and emits light with a maximum at 620 nm. 
Healthy cells with an intact membrane do not take up the dye while the dye 
permeates membranes of late-apoptotic or dead cells. Thus, living cells can be 
distinguished from dead cells which show an increased fluorescence signal. 
 
Protocol: 
7 x 105 cells per ml (24-well plate, 500 µl per well) were either left untreated or 
stimulated with cephalostatin 1. After incubation, cells were harvested by 
centrifugation (600 x g, 10 min) and washed once with PBS. Staining was 
carried out by resuspending the pellets each in 500 µl PI solution (2.5 µg PI in 
PBS). The probes were incubated for 5 min at room temperature and 
subsequently stored on ice. Measurement was performed in a flow cytometer 
(FACS Calibur, Becton Dickinson, Heidelberg, Germany) with the fluorescence 
channel 2 (FL-2, λem 585 nm) (for a more detailed description of flow cytometry 
see 5.1). Cells from 0 to 101 (arbitrary fluorescence units, logarithmic scale) in a 
histogram were regarded living while cells appearing in a peak around 103 were 
regarded apoptotic or dead. 
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5. QUANTIFICATION OF APOPTOSIS BY FLOW CYTOMETRY 
Apoptotic cells show several morphologic alterations. Among these are 
condensation and fragmentation of DNA and breakdown of the nucleus. Early in 
the apoptotic progress, phosphatidylserine is exposed on the outside of the 
plasma membrane. Provided that mitochondria are involved in the signal 
transduction, the dissipation of mitochondrial membrane potential is often 
observed in the intrinsic apoptotic pathway. Quantitative detection of these 
events can be accomplished by flow cytometry. 
5.1 INTRODUCTION TO FLOW CYTOMETRY 
Flow cytometry is a useful method for the measurement of cell size and 
granularity as well as the detection of fluorescent stains. Since apoptotic cells 
shrink and become more granulated, their light scatter pattern changes 
characteristically. DNA alterations or changes in the distribution of diverse 
proteins can be quantified by staining with appropriate fluorochromes. 
 
Principle:  
 
FACS buffer   
NaCl  8.12 g 
KH2PO4 0.26 g 
Na2HPO4 2.35 g 
KCl  0.28 g 
Na2EDTA 0.36 g 
LiCl  0.43 g 
Na-azide 0.20 g 
H2O  ad 1000 ml, pH 7.37 
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In a flow cytometer, cells travel in a laminar fluid stream past a focused laser 
beam. The morphologic features of a cell are measured by changes in the 
beam of laser light that are caused by a cell passing through this beam. Some 
of the incident light is scattered in the forward direction (forward scatter = FSC) 
and denotes the cell size as smaller particles scatter less light. Light scattered 
at right angles is a characteristic of the internal complexity of a cell (side scatter 
= SSC). These two parameters give rise to the dot plot. The relative intensity of 
fluorescent stains is measured with detectors appropriate to the specific 
emission spectrum of the fluorochrome and is represented in a histogram plot. 
5.2 QUANTIFICATION BY STAINING WITH PROPIDIUM IODIDE 
The DNA content of growing cells changes according to the cell cycle phase. In 
G0/G1, cells possess a DNA content of 2n (diploid). During S phase, the DNA is 
doubled and thus, the DNA content lies between 2n and the final 4n of the G2/M 
phase (mitosis). This particular distribution of cells in a growing culture can be 
made visible in a histogram plot by staining the cells with PI [86]. Since the dye 
intercalates into the DNA after permeabilisation, cells in G0/G1 emit a lower 
fluorescence intensity than cells in G2/M phase while cells in S phase appear 
between them. The intensity of the fluorescent light of a cell is directly 
proportional to its DNA content. In apoptosis, the DNA becomes fragmented. 
When the low molecular weight fragments are eluted from the cells by a 
hypotonic buffer, the cells take up less stain than cells with uncompromised 
DNA. These apoptotic cells appear at an intensity range lower than the G0/G1 
peak and are characterised as subG1 peak.  
 
Protocol: 
Cells were seeded at a concentration of 7 x 105 / ml in a 24-well plate (500 µl 
per well) and either left untreated or stimulated with cephalostatin 1. Stimulation 
concentrations, times and used inhibitors are listed in Table 4. After the 
appropriate period of time, cells were harvested by centrifugation (600 x g, 10 
min) and washed once with cold PBS. The pellets were resuspended in 500 µl  
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Table 4: Assay settings for quantitative detection of apoptosis. 
 
Experiment 
Concentration of 
cephalostatin 
1 
Stimulation 
period Preincubation 
Concentration-dependent 
induction of apoptosis 
(IV.2.2) 
 
0.001 – 10 µM 24 h  
Time-dependent induction 
of apoptosis (IV.2.2) 
 
1 µM 0 – 24 h  
Caspase involvement in 
cephalostatin 1-
induced apoptosis 
(IV.3.1.1) 
 
1 µM 24 h zVADfmk (1 h) 
Apoptosis induction in 
CD95 deficient cells 
(IV.3.2.2) 
 
1 µM 0 – 24 h  
Apoptosis induction in 
caspase-8 deficient 
cells (IV.3.2.2) 
 
1 µM 0 – 24 h  
Dependence of 
cephalostatin 1-
triggered apoptosis on 
caspase-9 (IV.3.3.6) 
 
1 µM 16 h zLEHDfmk (1 h) 
Inhibition of apoptosis by 
Bcl-2 or Bcl-xL 
overexpression 
(IV.3.3.7) 
 
1 µM 0 – 24 h  
Inactivation of Bcl-2 
(IV.3.3.8) 
 
1 µM 0 – 24 h  
 
hypotonic fluorochrome solution (HFS) and left overnight at 4°C in the dark. 
Untreated cells were used for adjustment of instrument settings. The 
fluorescence intensity (FL-2) as well as scatter parameters were acquired. The 
percentage of apoptotic cells was determined from the region of the subG1 
peak. 
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HFS (light protection!)  
Propidium iodide 50 µg 
Sodium citrate 0.1% (w/v) 
Triton X-100  0.1% (v/v) 
PBS   ad 1 ml 
5.3 QUANTIFICATION BY STAINING WITH ANNEXIN V  
Early in apoptosis, the cell membrane loses its normal asymmetry. The 
membrane phospholipid phosphatidylserine (PS) that is located almost 
exclusively on the cytoplasmic side of the membrane of living cells is 
translocated to the outside of the membrane by a phospholipid specific 
scramblase [27]. These exposed molecules are supposed to constitute the “eat-
me” signal to macrophages nearby which recognise the PS molecules on the 
surface and phagocytose the apoptotic cells [26].  
 
The annexin V assay makes use of this exposure of PS for the detection of cells 
in early or immediate apoptosis, even before events like DNA fragmentation can 
be measured. Annexin V is a small Ca2+ dependent protein with a high and 
selective affinity for PS. It can be tagged with FITC without compromising its 
binding properties to PS thus enabling the marked cells to be analysed by flow 
cytometry [88]. An additional staining with PI opens the opportunity to 
distinguish between live cells (no staining), apoptotic cells (Annexin V labeling, 
but no PI uptake) and dead cells (double staining).  
 
Protocol: 
The evaluation of phosphatidylserine exposure was carried out using an 
Annexin V-FITC Apoptosis Detection Kit from Calbiochem (Schwalbach, 
Germany) according to the manufacturer’s instructions. 
Cells (7 x 105 / ml, 1 ml, 24-well plate) were either left untreated or stimulated 
with cephalostatin 1 (1 µM) for different periods of time (0 – 24 h) and collected 
by centrifugation (600 x g, 4° C, 10 min). They were washed once with cold 
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PBS, resuspended in 500 µl cold 1 x binding buffer and incubated with 1.25 µl 
Annexin V-FITC solution for 15 min at room temperature. After another 
centrifugation step (600 x g, 4° C, 10 min), the pellet was resuspended in a 
volume of 500 µl cold 1 x binding buffer and 10 µl PI solution was added. The 
probes were set on ice in the dark and immediately analysed by FACS. The 
instrument settings were adjusted with apoptotic cells stained with Annexin-
FITC only (FL-1; λem: 530 nm) or with PI only (FL-2, λem: 585 nm). 
5.4 MEASUREMENT OF MITOCHONDRIAL POTENTIAL DISSIPATION 
The mitochondria are the site of energy production in a living cell. This 
production of ATP is driven by an electrochemical gradient consisting of a 
proton gradient and a transmembrane electrical potential (∆ψm) built across the 
inner membrane (180 - 220 mV, negative inside). The dissipation of this 
potential is often observed in apoptosis. Measurement of this event is made 
possible by the lipophilic fluorescent cation 5,5',6,6'tetrachloro-1,1',3,3'-
tetraethylbenzimidazol-carbocyanine iodide (JC-1) which selectively targets the 
mitochondria and localises to the inner membrane [89]. 
 
In living cells, the monomers form aggregates due to the potential of the 
membrane which emit light at approx. 590 nm when excited at 490 nm. The 
orange fluorescence can be analysed in the FL-2 channel of the flow cytometer. 
When the mitochondrial membrane is permeabilised, the potential-sensitive 
aggregates resolve into the monomers which causes a shift in emitted light from 
590 to 530 nm (green). This shift can be detected in the flow cytometer by an 
increase of cells being measured by the FL-1 (green) channel [90].  
 
Protocol: 
JC-1 (Molecular Probes, Eugene, USA) was solubilised in DMSO at a stock 
concentration of 5 mM. Solutions were stored at –20° C.  
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Untreated or cephalostatin 1-treated cells (7 x 105 / ml, 1 ml, 24-well plate; 
stimulation with 1 µM cephalostatin 1 for 0 – 24 h) were incubated with 1.25 µM 
JC-1 (final concentration) for 10 min at 37° C in the dark. Following staining, the 
probes were collected into polypropylene tubes and kept at 37° C in a water 
bath until measurement.  
 
Since the spectra of the fluorescent emissions of JC-1 aggregates and 
monomers overlap to a certain extent, a correction of the FACS measurement 
was necessary. Compensation of FL1 – FL2 was adjusted at 4 % and FL2 – 
FL1 was set at 12 %. 
 
The shift in fluorescent emission was also examined using fluorescence 
microscopy (see 6.2.2). 
6. MICROSCOPY 
6.1 LIGHT MICROSCOPY 
Morphologic changes of apoptotic cells such as shrinking, blebbing and 
formation of apoptotic bodies can be detected by visualisation in a light 
microscope.  
 
Cells at a concentration of 7 x 105 (24-well plate) were either left untreated or 
stimulated with 1 µM cephalostatin 1 for 24 h. After incubation, probes were 
viewed with a Zeiss Axiovert 25 microscope (Zeiss, Jena, Germany) at a 200 x 
magnification and pictures were taken with the connected reflex camera. 
6.2 FLUORESCENCE MICROSCOPY 
6.2.1 Hoechst staining 
A characteristic feature of an apoptotic cell is condensation of DNA followed by 
its fragmentation. Vital staining of DNA with Hoechst 33342 allows for 
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visualisation of DNA changes in a fluorescence microscope. After being taken 
up by an active transport mechanism, the dye binds AT pairs in the DNA and 
can be detected without any requirement for fixation [91]. Healthy cells emit only 
weak blue fluorescence since the DNA is distributed evenly in the nucleus. The 
nucleus in apoptotic cells is smaller in size and due to the condensed DNA 
shows a strong blue signal. Apoptotic bodies are visible as small clumped dots.  
 
Protocol: 
7 x 105 cells / ml (24-well plate, 1 ml) were either left untreated or stimulated 
with cephalostatin 1 (1 µM) for various periods of time. 10 µl of Hoechst solution 
were added (0.1 mg/ml stock concentration in distilled water) to each well and 
the plate was incubated at 37° C for 5-7 min. Subsequently, the plate was kept 
on ice until analysis. Pictures were taken with a Zeiss Axiovert 25 microscope 
(Zeiss, Jena, Germany) and connected camera using filter 02 (λex: 365 nm, λem: 
420 nm). 
6.2.2 JC-1 staining 
Samples were prepared as described under 5.4. Cells were viewed at 200 x 
magnification with a Zeiss Axiovert 25 microscope (Zeiss, Jena, Germany) 
using filter 09 (λex: 450-490 nm, λem: 520 nm). 
6.3 CONFOCAL LASER SCANNING MICROSCOPY (CLSM) 
CLSM differs from conventional microscopy in that it offers a higher optical 
resolution. This is accomplished by two conjugated pinholes, one illumination 
pinhole through which only a disk-shaped area is lighted and one in front of the 
detector which is focused on the same focal plane as the illumination pinhole 
and allows light solely from there to pass. Thus, out of focus blurs are cut off 
and image definition is enhanced. For the analysis of protein release from the 
intermembrane space of mitochondria an LSM 510 Meta (Zeiss, Jena, 
Germany) was used. It is equipped with different lasers which enable co-
localisations using different fluorochromes.  
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Protocol: 
Cells were seeded at 7 x 105 per ml and stimulated with cephalostatin 1 (1 µM) 
or etoposide (25 µg/ml) for 8 h. 4 x 104 cells were centrifuged onto glass slides 
in a cytospin funnel and dried at RT overnight. Samples were fixed and 
permeabilised with 4 % para-formaldehyde containing 0.05 % saponin in PBS 
for 15 minutes at room temperature. After washing with 0.03 % saponin in PBS, 
probes were blocked with 1 % BSA, 1 % FCS, 0.1 % Tween-20 in PBS for 1 h 
and washed twice in PBS. Anti-cytochrome c antibody and anti-Smac antibody 
were applied together (1 : 100 dilution in blocking buffer) for co-staining. The 
anti-AIF antibody was used in the same concentration. The antibody solutions 
(15 µl per sample) were brought up carefully after drying the glass slide in order 
to avoid spreading. After incubation for 1 h at RT, the samples were washed 
twice in PBS. Subsequently, the probes were incubated with the respective 
secondary antibodies, coupled to the fluorophores Alexa488 or Alexa633 (see 
) at a dilution of 1 : 200 in PBS for another 1 h. Finally, the slides were 
washed twice in PBS and a cover slip was fixed with mounting medium 
(DakoCytomation GmbH, Hamburg, Germany) which was allowed to solidify for 
at least 2 h.  
Table 7
 
Instrument settings for the laser-scanning microscope were applied as listed in 
. For co-staining, pictures were taken in multi-track mode. Table 5
Table 5: Instrument settings for confocal laser scanning microscopy. 
 
Fluorophore Excitation wavelength Detection filter 
Alexa488 480 nm (Argon laser) 505-530 nm BP 
Alexa633 633 nm (HeNe2 laser) 650 nm LP 
6.4 TRANSMISSION ELECTRON MICROSCOPY 
Electron microscopy offers the opportunity to examine samples on a very fine 
scale. Morphological details of cell structure and alterations of diverse cell 
organelles can be shown in high resolution. The “illumination” of the probe is 
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achieved by a beam of electrons. Where the sample is thicker or denser, fewer 
electrons are transmitted to the phosphor image screen behind and thus less 
light is generated.  
 
Preparation and electron microscopic analyses of the probes were performed 
by Prof. Dr. G. Wanner and Ms. Cornelia Niemann at the Botanical Institute, 
LMU Munich, Germany.  
 
Protocol: 
7 x 105 cells per ml (24-well plate; 1 ml) were either left untreated or stimulated 
with cephalostatin 1 (1 µM) for 0 – 16 h. Following stimulation, cells were 
harvested at 360 x g at 4°C for 10 min and washed with cold PBS. Again, 
probes were centrifuged, resuspended in fixative solution and stored at 4°C.  
 
Fixing buffer     Fixative solution     
75 mM cacodylate, pH 7,0   2.5 % glutaraldehyde in fixing buffer 
75 mM NaCl    
  2 mM MgCl2 
 
For primary fixation, probes were kept for at least 1 h in fixative solution. 
Subsequently, they were washed with fixing buffer for increasing lengths of time 
(5, 15, 30 and 60 min). Secondary fixation was accomplished by incubation with 
1 % OsO4 in fixing buffer. Finally, another washing step in fixing buffer for 15 
min was succeeded by a series of washings with distilled water (5, 30 and 60 
min). After fixation, the samples were dehydrated with a mixture of water and 
acetone of increasing acetone concentration.  
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Dehydration procedure: 
Duration Acetone concentration Additional stains 
15 min 10 %  
30 min 20 %  1 % uranyl acetate 
15 min 40 %  
15 min  60 %  
15 min 80 %  
15 min, 30 min, 60 min 100 %  
  
Once the probes had been transferred to the final dehydration fluid, they were 
embedded in Spurr low-viscosity epoxy resin. The infiltration process was 
carried out by increasing concentrations of epoxy resin in acetone: 
 
Duration Epoxy resin concentration
1 h 50 % 
2 – 5 h 66 % 
4 h 100 % 
 
Finally, probes were polymerised by heating to 65 – 70°C for 16 h. 
 
Pictures were taken at a LEO EM 912 with an integrated Ω energy filter in zero-
loss mode (LEO – Zeiss AG, Jena, Germany). 
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7. CASPASE ACTIVITY ASSAY 
Caspase activity can be detected by appearance of the active cleavage 
products which are generated from the caspase zymogens by western blot 
analysis (see 8). Another approach utilises the specificity of caspases for 
cleavage after aspartate residues in a particular peptide sequence. For 
caspase-3, this sequence is DEVD. The peptide is labelled with the fluorophore 
7-amino-4-trifluoromethyl coumarin (AFC) whose blue fluorescence shifts to 
green upon release from the substrate by active caspase-3. Caspase activity is 
directly proportional to the fluorescence signal. 
 
Protocol: 
Cells were seeded at 5 x 105 / ml in a 24-well plate and stimulated with 
cephalostatin 1 (1 µM) for different periods of time. For some experiments, a 
preincubation with 50 µM zLEHDfmk preceded stimulation. After treatment, cells 
were harvested by centrifugation (370 x g, 4° C, 10 min) and washed twice with 
ice-cold PBS. Pellets were resuspended in 100 µl lysis buffer and frozen at –80° 
C until next day. After defrosting, cell lysates were collected by centrifugation 
(14,000 x g, 4° C, 10 min). 10 µl of each supernatant (triplicates) were 
transferred to two 96-well flat bottom plates – one for caspase activity assay, 
one for protein determination.  
 
Lysis buffer     Buffer B    
  5 mM MgCl2    50 mM HEPES, pH 7.5 
  1 mM EGTA         1 % Sucrose 
 0.1 % Triton X-100      0.1 % CHAPS 
25 mM HEPES, pH 7.5 
 
Substrate solution (prepare immediately before experiment) 
Buffer B    9 ml 
10 mM DEVD-AFC in DMSO 45 µl 
16 % DTT    100 µl 
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For caspase activity assay, 190 µl of substrate solution were added to each 
well. At once, the first reading was performed in a Tecan SPECTRAFluor Plus 
plate reader (λex: 390 nm, λem: 535 nm; Tecan, Crailsheim, Germany) using 
Xfluor 4 software. The following measurements were carried out in 30 minute 
intervals up to 2.5 h.  
 
Protein determination was carried out as described under 8.2. 
 
For interpretation of results, the readings were normalised by the protein 
concentration. The actual activity was calculated by evaluating the difference 
between the 1.5 h interval and the 2 h interval. 
8. WESTERN BLOT ANALYSIS 
8.1 PREPARATION OF SAMPLES 
8.1.1 Whole cell lysates 
 
Lysis buffer Lysis buffer for phosphorylated proteins 
(prepare immediately before experiment) 
 
  30 mM Tris-HCl, pH 7.5 
150 mM NaCl 
    2 mM EDTA 
       1 % Triton X-100 
              CompleteTM 
 
    2 mM EDTA 
137 mM NaCl 
     10 % Glycerol 
    2 mM Na4P2O7 
  20 mM Tris-base 
       1 % Triton-X 100 
  20 mM C3H7Na2O6P 
  10 mM NaFl 
    2 mM Na3VO4 
    1 mM PMSF 
              CompleteTM 
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Cells were seeded in 24-well plates (8 x 105 per ml; 1 ml) and either left 
untreated or stimulated with cephalostatin 1 (1 µM) for 0 – 24 h. For harvest, 
three wells were pooled and centrifuged at 360 x g, 4° C for 10 min. The pellet 
was washed in cold PBS. After another centrifugation, the pellet was 
resuspended in 100 µl lysis buffer and stored on ice for 30 min. The solution 
was cleared by centrifugation (10,000 x g, 4° C, 10 min) and the protein solution 
transferred to fresh tubes. Protein determination was performed following the 
protocol of Bradford (see 8.2). The protein solution was diluted 1 : 5 with 5 x 
sample buffer, boiled at 95° C for 5 min and stored at –20° C or used directly for 
electrophoresis. 
 
Sample buffer (5 x)     
3.125 M Tris-HCl, pH 6.8  100 µl 
Glycerol    500 µl 
20 % SDS    250 µl 
16 % DTT    125 µl 
5 % Pyronin Y       5 µl 
H2O       20 µl 
8.1.2 Cytosolic and particulate fractions 
In apoptosis, factors from the intermembrane space of mitochondria are 
released into the cytosol where they form part of activation complexes for 
caspases (e. g. cytochrome c, Smac) or they translocate into the nucleus where 
they participate in DNA fragmentation (Endonuclease G, AIF). For analysis of 
release of these factors, the cytosol has to be separated from the mitochondria. 
This is accomplished by a permeabilisation buffer containing a low 
concentration of digitonin which forms complexes with cholesterin in the cell 
membrane. Thus, small pores develop through which the cytosol is eluted into 
the iso-osmotic buffer while organelles are retained inside the cell. The protocol 
was carried out following the procedure of Leist et al. [92] in a modified version.  
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Permeabilisation buffer 
210 mM Mannitol 
  70 mM Sucrose 
  10 mM Hepes pH 7.2 
 0.2 mM EGTA 
    5 mM Succinate 
0.15 % (w/v) BSA 
60 µg/ml Digitonin 
 
Protocol: 
Cells were seeded and stimulated as for whole cell lysate preparation. Three 
wells for each probe were pooled and centrifuged at 360 x g, 4° C for 10 min. 
The supernatant was discarded thoroughly. The pellets were resuspended 
carefully in 100 µl permeabilisation buffer and incubated on ice for 20 min. The 
cytosolic fraction was obtained by centrifugating the solution at 360 x g (4° C, 
10 min) and the supernatant was cleared of any remaining cell fragments at 
13,000 x g (4° C, 10 min). The pellet of the first centrifugation after 
permeabilisation containing the mitochondria, the other organelles and the 
membranes was resuspended in 0.1 % Triton-X 100 in PBS (100 µl) and lysed 
for 15 min on ice. The supernatant of a subsequent centrifugation step  
(13,000 x g; 4° C; 10 min) constitutes the mitochondria-enriched fraction. This 
fraction is referred to as mitochondrial fraction in the “Results” section. 
 
Protein determination was carried out with the Bradford method (see 8.2). The 
probes were diluted with 5 x sample buffer and boiled at 95° C for 5 min. 
Afterwards, they were separated by SDS-PAGE immediately or stored at  
–20° C. 
8.2 PROTEIN DETERMINATION 
The method developed by Bradford [93] makes use of the feature of Coomassie 
Brilliant Blue G-250 to change its absorption maximum from 465 nm to 595 nm 
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on binding to proteins. The protein content of the lysates can thus be quantified 
by comparing the absorption with a calibration curve prepared with increasing 
concentrations of BSA in H2O.  
 
Measurement was performed in ELISA plates in an SLT Spectra ELISA reader 
(SLT, Crailsheim, Germany). Cell lysates were diluted 1 : 10 in H2O. 190 µl of 
Bradford solution (BioRad, Hercules, USA; diluted 1 : 5 in H2O) were added to 
10 µl lysate solution and 5 minutes were allowed for the colour shift to develop. 
Plates were measured at 592 nm. 
8.3 SDS-PAGE 
The protein samples described above are separated by denaturing SDS-
polyacrylamide gel electrophoresis according to Laemmli [94]. Sodium dodecyl 
sulfate (SDS) is an anionic detergent which binds to the hydrophobic parts of 
the proteins and solubilises them. Thereby, proteins lose secondary and tertiary 
structures and only retain their primary structure. SDS confers a high negative 
charge to the proteins proportional to the length of the amino acid chain thus 
covering any charges the proteins displayed themselves. In an electric field, the 
negatively charged proteins are drawn towards the anode and they are 
separated solely on the basis of their size by the pores of the polyacrylamide 
gel. Further unfolding of the proteins is achieved by adding the reducing agent 
dithiothreitol (DTT) by which disulfide bonds inside the proteins are cleaved.  
 
The molecular weight is determined by comparison with molecular weight 
standard mixtures (Rainbow marker RPN 755, Amersham, Freiburg, Germany) 
or prestained Precision Protein Standards, BioRad, München, Germany). 
All protein separations were carried out in discontinuous gel electrophoresis 
where a stacking gel allows proteins to be concentrated in a line before they 
enter the separation gel. The concentration of the separation gel was adjusted 
depending on the size of the protein to be detected (see Table 6). 
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Table 6: Used gel concentrations for SDS-PAGE. 
 
Analysed protein Gel concentration 
Apaf-1 / BiP / calpain / PARP 7.5 % 
caspase-8 / caspase-9 / pJNK 10 % 
Bcl-2 / pBcl-2 / Bcl-xL / caspase-3 / 
caspase-7 / caspase-12 / 
CHOP / XIAP 
12 % 
AIF / cytochrome c / Smac 15 % 
 
Electrophoresis was carried out using a vertical apparatus Mini Protean II 
(BioRad, Hercules, USA) which allows two gels to be run in parallel. 
 
For gel preparation an acrylamide 30 % / bis-acrylamide 0.8 % 37.5 : 1 (v/v) 
stock solution (RotiphoreseTM Gel 30, Roth, Karlsruhe, Germany) was used. 
 
Samples with equal amount of protein and the molecular weight marker were 
loaded into the slots of the prepared polyacrylamide gels. Electrophoresis was 
run at 100 V for 21 min for stacking and at 200 V for separation of the protein 
mixture (power supply: Biometra, Göttingen, Germany). 
 
Separation gel 12%     Stacking gel     
PAA solution 30 %  6.0 ml   PAA solution 30 %  1.7 ml 
1.5 M Tris, pH 8.8  3.75 ml  1.5 M Tris, pH 8.8  1.0 ml 
SDS 10 %   0.15 ml  SDS 10 %   0.1 ml 
H2O    5.1 ml   H2O    7.0 ml 
TEMED   15 µl   TEMED   20 µl 
APS    75 µl   APS    100 µl 
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Electrophoresis buffer   
Tris base   3 g 
Glycine   14.4 g 
SDS    1.0 g 
H2O         ad 1000 ml 
8.4 WESTERN BLOTTING AND DETECTION OF PROTEINS 
For detection of the protein of interest, the protein bands are transferred after 
electrophoresis onto blotting membranes, incubated with specific antibodies and 
visualised by chemiluminescence reagents.  
 
Anode buffer      Cathode buffer   
5 x Tris-CAPS 20 ml    5 x Tris-CAPS 20 ml 
Methanol  15 ml    SDS 10 %    1 ml 
   ad 100 ml      ad 100 ml 
 
5 x Tris-CAPS   
Tris   36.34 g 
CAPS   44.26 g 
   ad 1000 ml 
 
The western blot was carried out by semi-dry blotting using a discontinuous 
buffer system. Polyvinylidene membranes (Immobilon-P; Millipore, Bedford, 
USA) were activated by soaking in methanol for 5 minutes followed by at least 
30 minutes in anode buffer. The transfer stack consisted of a thick blotting 
paper (BioRad, Hercules, USA) wetted in anode buffer, followed by the 
membrane, the gel and finally a second thick blotting paper soaked in cathode 
buffer. The transfer was performed on a Transblot SD semidry transfer cell 
(BioRad, Hercules, USA) at 1.5 mA / cm2 for 40-60 minutes depending on the 
size of the protein to be detected. After transfer, the membranes were blocked 
in 5 % non-fat dry milk in TBS-T for 1 h at RT. Subsequently, the membrane 
III Materials and Methods  45 
was immersed in the respective antibody solution (see Table 7) diluted in 1 % 
non-fat dry milk in TBS-T overnight at 4° C. After three wash steps in TBS-T for 
10 minutes each, the adequate secondary horseradish peroxidase-labeled 
antibody was applied for 1 h at RT.  
Table 7: Primary antibodies 
 
Antibody Isotype Dilution Company 
AIF Rabbit IgG 1 : 1000 Chemicon, Hofheim, Germany 
Apaf-1 Mouse IgG1 1 : 250 BD Transduction Laboratories, 
Heidelberg, Germany 
Bcl-2 Mouse IgG1 1 : 250 Upstate, Lake Placid, USA 
phospho-Bcl-2 Rabbit IgG 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
Bcl-xL Rabbit IgG 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
BiP / GRP78 Mouse 
IgG2a 
1 : 250 BD Transduction Laboratories, 
Heidelberg, Germany 
Calpain Mouse IgG1 1 : 1000 Chemicon, Hofheim, Germany 
Caspase-3: HRPO Mouse 
IgG2a 
1 : 1000 BD Transduction Laboratories, 
Heidelberg, Germany 
Caspase-7 Mouse IgG1 1 : 1000 BD Pharmingen, Heidelberg, 
Germany 
Caspase-8 Mouse 
IgG2b 
1 : 1000 Upstate, Lake Placid, USA 
Caspase-9 
(Western Blot) 
Mouse IgG1 1 : 100 Calbiochem, Bad Soden, 
Germany 
Caspase-9 
(Immunoprecipitation) 
Rabbit IgG  Sigma-Aldrich, München, 
Germany 
Caspase-12 Rabbit IgG 1 : 1000 Cell Signaling, Frankfurt, 
Germany 
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Antibody Isotype Dilution Company 
GADD153 / CHOP10 Rabbit IgG 1 : 250 Sigma-Aldrich, München, 
Germany 
PARP Mouse IgG1 1 : 100 Calbiochem, Bad Soden, 
Germany 
phospho-JNK Mouse IgG1 1 : 2000 Cell Signaling, Frankfurt, 
Germany 
Smac/DIABLO Rabbit IgG 1 : 500 Biozol, Eching, Germany 
XIAP Mouse IgG1 1 : 250 BD Transduction Laboratories, 
Heidelberg, Germany 
 
Development of the blot was carried out after three more washings (TBS-T, 10 
minutes each) with the ECL Plus substrate solution (Amersham Biosciences, 
Freiburg, Germany). Thereafter, the membrane was exposed to X-ray film for 
the appropriate time period which was developed in a tabletop film processor 
(Curix 60, Agfa, Köln, Germany). 
8.5 COOMASSIE STAINING OF GELS 
After protein transfer, gels were stained with Coomassie blue (anazolene) to 
ensure equal protein loading and blotting efficiency. Proteins are fixed inside the 
gel by acetic acid which prevents diffusion of the bands.  
 
Staining solution (filtration before storage) Destaining solution    
Coomassie blue 0.3 %    Glacial acetic acid  10 % 
Glacial acetic acid 10 %    Ethanol   30 % 
Ethanol  45 %    H2O 
H2O 
 
Gels were stained for 30 minutes on a shaking platform and subsequently 
destained in several loads of destaining solution until the proteins appeared as 
clearly defined blue bands. 
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8.6  MEMBRANE STRIPPING 
In order to detect different proteins successively on PVDF membranes, bound 
antibodies resulting from previous experiments have to be removed. For that 
purpose, membranes were immersed in stripping buffer (65.2 mM Tris-HCl, pH 
6.8, 2 % SDS, 100 mM 2-Mercaptoethanol) and treated for 30 minutes at 50° C 
on a shaking platform. Subsequently, remnants of stripping buffer were washed 
away by three wash steps in TBS-T (10 minutes, RT). Stripping efficiency was 
confirmed by applying ECL Plus substrate solution (see 8.4). When no bands 
became apparent the membrane was blocked again to cover unspecific binding 
sites with 5 % non-fat dry milk in TBS-T for 1 h at RT. Afterwards, the next 
primary antibody was brought up. 
9. IMMUNOPRECIPITATION 
Immunoprecipitation is used for the enrichment of certain proteins from cell 
lysates. For that, antibodies specific for the protein of interest are added to the 
cell lysate. After formation of the antigen-antibody-complex, this complex is 
precipitated with Protein A, a bacterial protein with high affinity to the Fc part of 
immunoglobulins. Once the protein is dissociated from the immune complex, 
the protein and any bound ligands can be analysed by Western blot. 
 
Protocol: 
Cells were treated and harvested as described under 8.1. In the meantime, for 
each sample, 50 µl of a solution of protein A, immobilised on agarose beads, 
were centrifuged shortly and resuspended in lysis buffer. 2.5 µl of the respective 
antibody were added to 50 µl bead solution and mixed gently for 1 h at RT. 
After this time, the bead solutions were centrifuged (3,000 x g, 2 minutes, 4° C) 
and carefully washed three times with lysis buffer. Once the protein 
concentration of the cell lysates had been determined (see 8.2), 300 – 400 µg 
protein were filled up to a final volume of 250 µl with lysis buffer and added to 
the bead solution. In order to allow the immune complexes to form, the samples 
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were mixed overnight at 4° C by end-over-end rocking. Afterwards, the 
precipitates were harvested by centrifugation (3,000 x g, 4° C, 2 minutes). 40 µl 
of the supernatant were kept as binding control. The pellet was washed three 
times with lysis buffer. After the last wash solution had been removed 
completely, sample buffer containing 2-mercaptoethanol was added to the pellet 
and the probe is heated to 95° C for 5 minutes to dissolve the protein from the 
precipitate. The beads were removed by centrifugation. 30 µl of each 
supernatant were analysed by Western blot as described under 8. 
10. COMET ASSAY / SINGLE CELL GEL ELECTROPHORESIS 
The comet assay allows for rapid detection of DNA damage in single cells. Cells 
embedded in agarose are lysed and electrophoresed in alkaline conditions 
enabling the detection of DNA single and double strand breaks. 
 
Protocol: 
The assay was carried out following the manufacturer’s instructions (Trevigen 
Inc, Gaithersburg, MD, USA). All steps were performed under dimmed light to 
prevent DNA damage by UV light.  
 
Cells were seeded at 6 x 105 / ml in a 24-well plate and either left untreated or 
stimulated with cephalostatin 1 (1 µM) or etoposide (10 µM) for 4 h. Harvest 
was performed by centrifugation at 360 x g, 4° C for 10 min. Pellets were 
resuspended in ice cold PBS to give a final concentration of 1 x 105 cells / ml. 
Meanwhile, the LMAgarose was molten and kept at 37° C. Cell suspension and 
agarose were carefully mixed at a ratio of 1 : 10 and 75 µl were immediately 
pipetted onto a microscope slide (CometSlide). In order to allow solidification 
of the agarose, slides were placed at 4° C in the dark for 10 min. Successively, 
slides were immersed in Lysis Solution (2.5 M sodium chloride, 100 mM EDTA, 
pH 10, 10 mM Tris Base, 1 % sodium lauryl sarcosinate, 1 % Triton-X-100) for 
40 min at 4° C and then in alkaline solution (300 mM NaOH, 200 mM EDTA) for 
40 min at RT. Electrophoresis was carried out under alkaline conditions in 300 
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mM NaOH, 1 mM EDTA at 1 V / cm (distance between the electrodes) and 300 
mA for 30 min at 4° C. Finally, slides were neutralised by dipping several times 
in H2O and air dried overnight. The samples were stained with 50 µl of diluted 
SYBR Green solution per agarose circle. Pictures were taken at a Zeiss 
Axiovert 25 microscope (Zeiss, Jena, Germany) using filter 09 (λex: 450-490 nm, 
λem: 520 nm). 
11. STATISTICS 
All experiments were performed at least three times. Results are expressed as 
mean ± SEM. Statistical analysis was performed by ANOVA with Bonferroni 
multiple comparison post-test or by unpaired two-tailed Student t-test. P values 
< 0.05 were considered significant. Analysis was performed with GraphPad 
PRISM software, Version 3.02 (GraphPad Software Inc., San Diego, USA). 
 
 
 
IV. RESULTS 
1. CYTOTOXIC ACTIVITY OF CEPHALOSTATIN 1 
Cephalostatin 1 shows a remarkable cytotoxicity profile in the NCI-60 panel 
(see II.2). For the Jurkat cells in use here, the cytotoxic effect was investigated 
with the MTT assay (see III.4.1). As depicted in Figure 20, cell viability is 
affected already at 0.1 nM cephalostatin 1 with the maximal effectivity being 
reached at 10 µM. The IC50 calculated from these results is 1.25 nM. 
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Figure 11: Cytotoxic effects of cephalostatin 1 in Jurkat cells. 
Cells were stimulated with cephalostatin 1 (concentrations as indicated) for 24 h. Impairment of 
cell viability was analysed by an MTT assay as described in Materials & Methods. Bars 
represent the mean ± SE of three independent experiments performed in triplicate. *** p < 0.001 
(ANOVA / Dunnett) 
2. APOPTOSIS-INDUCTION BY CEPHALOSTATIN 1 
The next step consisted in evaluation of the type of cell death induced by 
cephalostatin 1. Several methods were undertaken in order to deduce if 
cephalostatin 1 induces apoptosis.  
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2.1 MORPHOLOGIC ALTERATIONS 
2.1.1 Light microscopic analysis of cephalostatin 1-treated cells 
As described in II.4, during apoptosis, the cell undergoes distinct morphologic 
changes such as cell shrinkage and the formation of apoptotic bodies. 
Cephalostatin 1 treatment (1 µM, 24 h) induces apoptotic body formation as 
indicated by the arrows in Figure 12.  
 
Control Cephalostatin 1
 
Figure 12: Lightmicroscopic picture of Jurkat T cells. 
After incubation with cephalostatin 1 (1 µM, 16 h), pictures were taken from untreated cells 
(control, left panel) or cephalostatin 1-stimulated cells (right panel). Arrows indicate apoptotic 
bodies.  
2.1.2 Morphologic analysis per flow cytometry 
Changes in size and granularity are detectable by flow cytometric 
measurement. The decrease in cell size observed in apoptosis leads to lower 
forward scatter values while an increase in granularity is visualised in the dot 
plot as higher sideward scatter values (see III.5.1). As demonstrated in 
, cephalostatin 1 stimulation (1 µM, 24 h) leads to cell shrinkage (shift of the 
cell cloud to the left) and an augmentation of cellular granularity (shift of the cell 
cloud towards the top).  
Figure 
13
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Figure 13: Measurement of cell size and granularity by FACS. 
Untreated cells or cells incubated with cephalostatin 1 (1 µM, 24 h) were analysed by flow 
cytometry as described under Materials & Methods. Etoposide (25 mg/ml, 24 h) served as 
positive control. 
2.1.3 Morphologic changes of the nucleus 
Apoptotic nuclei are a site of numerous biochemical processes. The chromatin 
is condensed by enzymatic action of EndoG and other enzymes and finally the 
DNA is fragmented by cleavage between the histones, e.g. by CAD (caspase-
activated DNase), thus inducing evenly sized fragments of 192 bp and multiples 
thereof [95].  
 
By staining with Hoechst 33342, condensation and fragmentation of DNA was 
shown clearly for cephalostatin 1-treated cells in Figure 14. The DNA of 
untreated cells (left panel) is dispersed evenly across the nucleus and visible as 
faint blue circles. In the middle panel (8 h of stimulation), the colour intensity is 
increased indicating condensed chromatin and some cells display DNA 
fragments. The right panel (16 h of stimulation) shows the majority of cells with 
fragmented DNA. 
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Control
   
Cephalostatin 1, 8 h
 
Cephalostatin 1, 16 h
 
Figure 14: Nuclear changes on cephalostatin 1 treatment. 
Cells were treated with cephalostatin 1 (1 µM) for 8 h and 16 h. After incubation, cells were 
stained with Hoechst 33342. Representative pictures of untreated (Control) and treated cells are 
shown.  
2.1.4 Phosphatidylserine exposure 
Phosphatidylserine (PS), an aminophospholipid normally located in the cytosolic 
layer of the plasma membrane, is translocated to the outside of the membrane 
by scramblases in apoptotic conditions. Once outside, it serves as signal for 
phagocytes and other neighbouring cells thus triggering removal of the 
apoptotic cells.  
 
Cephalostatin 1 induces prominent PS exposure as indicated in Figure 15. 
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Figure 15: Measurement of PS exposure by Annexin V staining. 
FACS analysis of annexin V-FITC and PI-stained cells, either left untreated, stimulated with 
cephalostatin 1 (1 µM) for 8 – 24 h or with etoposide (25 µg/ml, 8 h) as positive control. Cells 
appearing at the lower right quadrant show positive annexin V-FITC staining indicating 
phosphatidylserine exposure on the cell surface and no DNA staining with PI proving intact cell 
membranes.  
2.2 QUANTITATIVE ANALYSIS OF CEPHALOSTATIN 1-INDUCED APOPTOSIS  
The fragmentation of DNA followed by disintegration of the cell into the 
apoptotic bodies which may contain part of the DNA fractions results in reduced 
DNA content. DNA content changes during the four phases of the cell-division 
cycle. Somatic cells are diploid (2n) in the G0/G1-phase (gap phase 0/1) and 
double the DNA in the S-phase (synthesis phase) (4n). Finally, in mitosis (M-
phase) after G2-phase, cells divide and the resulting two daughter cells are 
again diploid. The amount of cellular DNA can be visualised by DNA staining 
and subsequent flow cytometry (see III.5.2). Untreated Jurkat cells display the 
normal cell cycle distribution (Figure 16, control). After cephalostatin 1 treatment 
(1 µM, 24 h), peaks left of the G0/G1 peak appear representing the apoptotic 
cells with a lower DNA content than cells in G0/G1-phase. These peaks are 
IV Results  55 
referred to as sub-G0/G1 peaks. Etoposide (25 µg/ml, 24 h) was used as 
positive control. 
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Figure 16: Detection of cephalostatin 1-induced apoptosis by PI staining. 
FACS analysis of PI-stained nuclei of cells left untreated, stimulated with cephalostatin 1 (1 µM) 
or etoposide (25 µg/ml) for 24 h. Histograms demonstrate the distribution of nuclei according to 
their DNA content. Counts left of the G1-peak (gated) indicate the appearance of nuclei with 
subdiploid DNA content.  
Quantification of the sub-G0/G1 peak shows that cephalostatin 1 induces dose- 
and time-dependent apoptosis in Jurkat T cells.  
 
Already concentrations of 1 nM cephalostatin 1 triggered a significant increase 
in apoptosis (Figure 17, 24 h). The highest percentage of apoptosis was 
reached at 1 µM cephalostatin 1. Therefore, this concentration was chosen for 
further experiments. The response of the Jurkat cells to cephalostatin 1 
proceeded time-dependently with the first significant apoptotic level reached at 
6 h of stimulation (Figure 18). 
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Figure 17: Cephalostatin 1-induced apoptosis is dose-dependent. 
Cells were stimulated with increasing concentrations of cephalostatin 1 for 24 h. % Apoptotic 
cells denote the percentage of cells with subdiploid DNA content. Bars represent the mean ± SE 
of three independent experiments performed in triplicate. ** p < 0.01 (ANOVA / Dunnett). 
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Figure 18: Cephalostatin 1-induced apoptosis proceeds time-dependently. 
Cells were stimulated with cephalostatin 1 (1 µM) for 0 – 24 h. % Apoptotic cells indicate the 
percentage of cells with subdiploid DNA content. Bars represent the mean ± SE of three 
independent experiments performed in triplicate. ** p < 0.01 (ANOVA / Dunnett). 
3. SIGNAL TRANSDUCTION IN CEPHALOSTATIN 1-INDUCED APOPTOSIS 
3.1 CASPASES ARE ESSENTIAL FOR CEPHALOSTATIN 1-INDUCED 
 APOPTOSIS 
Caspases are the major executors of apoptosis induced by numerous stimuli. 
However, a growing body of evidence suggests that apoptotic cell death can 
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also be mediated by calpains [96], cathepsins [97] and AIF [98] to name but a 
few alternative enzymes.  
3.1.1 Inhibition of apoptosis by zVADfmk 
In order to prove if cephalostatin 1-induced apoptosis is dependent on caspase 
activity, cells were preincubated for 1 h with the broad spectrum caspase 
inhibitor zVADfmk (25 µM). Caspase inhibition prevented cephalostatin 1-
triggered apoptosis (1 µM, 24 h) indicating that the signal pathway relies on 
caspases (Figure 19). 
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Figure 19: The pan-caspase inhibitor zVADfmk prevents cephalostatin 1-triggered 
apoptosis. 
Cells were left untreated (Co), incubated with cephalostatin 1 (1 µM, 24 h) or pretreated with 
zVADfmk (25 µM, 1 h) and subsequently treated with cephalostatin 1 (1 µM, 24 h). Apoptotic 
cells were quantified by flow cytometry. Bars represent the mean ± SE of three independent 
experiments performed in triplicate. ** p < 0.01 (ANOVA / Dunnett). 
Caspase-3 belongs to the effector caspases downstream in the caspase 
cascade. Activated by the initiator caspases, it plays the most prominent role in 
the effector phase [99]. The substrates cleaved by caspase-3 include 
cytoplasmic and nuclear proteins, proteins involved in DNA repair, cell cycle 
and apoptosis regulation and several kinases [38]. The cleavage of PARP, a 
DNA repair enzyme, is regarded as proof of caspase-3 activity. 
 
Cephalostatin 1 (1 µM, time points indicated) induces caspase-3 activation after 
8 h as shown in Figure 20 A. The appearance of the active fragment (p17) at  
8 h correlates with cleavage of PARP (B) and also with the first significant 
increase in fluorescence intensity detected by the caspase activity assay (C).  
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Figure 20: Caspase-3 activation by cephalostatin 1 (1 µM). 
Representative Western blots showing time-dependent (0 – 24 h) cleavage of caspase-3 to its 
active subunit (p17, A) and of PARP (B) after cephalostatin 1 treatment (1 µM). Both 
experiments were performed three times with consistent results. C, caspase-3 activity in 
cephalostatin 1-stimulated cells. Bars represent the mean ± SE of three independent 
experiments performed in triplicate. ** p < 0.01, *** p < 0.001 (ANOVA / Dunnett). 
3.2 INVOLVEMENT OF THE CD95 PATHWAY 
As described in II.5.2, activation of death receptors by their ligands ensues 
activation of caspase-8 as initiator caspase. Subsequently, caspase-8 is able to 
induce caspase-3 cleavage.  
3.2.1 Activation of caspase-8 
In order to investigate the involvement of caspase-8 in signalling transduction, 
cleavage products of caspase-8 were detected by Western blotting. Cleavage of 
caspase-8 produces two intermediates (p42 and p44) which are further 
processed to the active 20 kDa fragment. Jurkat cells were treated with 
cephalostatin 1 (1 µM) for the indicated times. Figure 21 demonstrates that 
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cephalostatin 1 led to an activation of caspase-8 at 16 h. Compared to the 
apoptosis induction reaching significant levels already after 6 h, the activation of 
an initiator caspase 10 h later suggests that caspase-8 only plays a subordinate 
role in cephalostatin 1-induced apoptosis. 
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Figure 21: Caspase-8 activation by cephalostatin 1. 
Caspase-8 cleavage after incubation with cephalostatin 1 (1 µM, 0 – 24 h) to the p42 and p44 
cleavage products. One representative Western blot out of three is shown.  
3.2.2 Apoptosis induction in CD95 deficient cells 
The question if cephalostatin 1 employs death receptors for apoptotic signaling 
was addressed using Jurkat cells deficient in the CD95 receptor (subclone 
JurkatR) and Jurkat cells deficient in caspase-8. Effects were compared to S-
Jurkat cells (especially sensitive to the CD95 ligand (CD95-L) and used as 
basis for the deletion of CD95) and to the subclone A3 (providing the basis cell 
line for the caspase-8 deletion). The JurkatR cell line was stimulated for 24 h 
with the concentrations given in Figure 22 A. For the caspase-8 deficient cells, a 
time course was prepared with 1 µM cephalostatin 1 (Figure 22 B).  
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Figure 22: Involvement of the CD95 receptor system in cephalostatin 1-induced 
apoptosis. 
A, Jurkat and JurkatR cells were treated with the indicated concenctrations of cephalostatin 1 for 
24 h. B, Jurkat A3 and Jurkat caspase-8-/- cells were stimulated with cephalostatin 1 (1 µM) for 
different periods of time (0 – 24 h). C, Jurkat A3 (left panel) and Jurkat caspase-8-/- cells (right 
panel) were either left untreated (Co), treated with soluble CD95 ligand (CD95-L, 200 ng/ml) or 
etoposide (E, 25 µg/ml) for 24 h. Apoptotic cells were quantified by FACS analysis. All 
experiments were carried out three times in triplicate. Data points and bars represent the mean 
± SE. ** p < 0.01 (ANOVA / Dunnett). 
Compared to their controls, the JurkatR cells responded equally to cephalostatin 
1 treatment indicating that the CD95 receptor is not required for cephalostatin 1-
induced apoptosis. Since other death receptors such as TNF receptor or TRAIL 
receptor also involve caspase-8 as initiator caspase, caspase-8-/- cells were 
incubated with cephalostatin 1. However, no reduction in apoptosis could be 
detected compared to control cells. In order to assure that no functional 
caspase-8 was expressed, A3 and caspase-8-/- cells were stimulated with 
soluble CD95-L (200 ng/ml) and etoposide (25 µg/ml). As expected, caspase-8 
deficient cells were protected against CD95-L, but not against etoposide (C).  
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Thus, lack of CD95 receptor or caspase-8 does not interfere with apoptosis 
induction by cephalostatin 1 suggesting that the extrinsic pathway is not 
essential for cephalostatin 1-induced apoptosis. It is possible, though, that 
caspase-8 activation acts as amplification loop. 
3.3 INVOLVEMENT OF THE MITOCHONDRIA 
Mitochondria are part of the intrinsic apoptotic pathway and provide factors vital 
for the activation of initiator caspase-9, for DNA fragmentation and inhibitors for 
proteins which may prevent caspase activity (see II.5.3). In many apoptotic 
models, the dissipation of the mitochondrial inner membrane potential (∆ψm) that 
is essential for ATP production in physiological conditions is one of the first 
events in the mitochondrial pathway. Permeabilisation of the outer membrane is 
involved in the release of apoptogenic factors from the intermembrane space. 
3.3.1 Morphological alterations of cephalostatin 1-activated mitochondria 
Mitochondrial swelling and subsequent rupture of the outer mitochondrial 
membrane are considered one mechanism mediating the release of 
apoptogenic factors [100]. These changes are detectable on the ultrastructural 
level by transmission electron microscopy.  
 
As depicted in , the mitochondria of untreated cells have only little 
contrast relative to the cytoplasm (A, B, black arrows). The membrane system 
of the endoplasmic reticulum (ER) appears normal (B, red arrow). Upon 
stimulation with cephalostatin (1 µM) for 16 h, immense changes occur in the 
cells. The nuclei are condensed and fragmented and the nuclear membranes 
are dilated (D, blue arrows). Similarly, the ER membranes are enlarged and 
vesicles which are presumably ER-derived accumulate in the cytoplasm (E, 
asterisks). Most surprisingly, the mitochondria in cephalostatin 1-treated cells  
Figure 23
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Figure 23: Electron microscopic analysis of cephalostatin 1-mediated mitochondrial 
changes. 
Cells were left untreated (A, B) or stimulated with cephalostatin 1 (1 µM, 16 h) (C, D, E). 
Electron micrographs were prepared as described under Materials & Methods. A, C, 1 : 5,000 
fold magnification; B, D, E 1 : 10,000 fold magnification. Black arrows indicate mitochondria, 
blue arrows point to enlarged nuclear membranes and red arrows denote ER membranes. 
Asterisks demonstrate the vesicles that accumulate in the cytoplasm upon cephalostatin 1 
treatment. N, nucleus. 
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appear smaller with increased electron density compared to the untreated cells 
suggesting a condensation of the mitochondrial matrix. In contrast, the cristae 
appear blurred and swollen (C, insert). 
3.3.2 Alterations of the mitochondrial membrane potential 
The dissipation of the mitochondrial membrane potential was visualised by 
staining with the mitochondria-targeted dye JC-1 (see III.5.4). Mitochondria of 
Jurkat control cells display mainly an orange fluorescence from the JC-1 
aggregates indicating unchallenged membrane function (Figure 24, A). During 
the time course of cephalostatin 1 treatment (1 µM), the fluorescence 
increasingly shifts to a green colour as the JC-1 aggregates dissolve into 
monomers due to dissipation of the membrane potential. Etoposide (25 µg/ml) 
was used as positive control. 
 
A quantification of membrane permeabilisation was carried out by flow 
cytometry (Figure 24 B). Cells with green fluorescence indicating a disturbed 
gradient were counted at each time point. The first significant increase was 
detected after 8 h and cells with dissipated ∆ψm made up more than 70 % after 
24 h. This suggests that the mitochondria are affected by cephalostatin 1 
treatment and might play a role in the signal transduction. 
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Figure 24: JC-1 staining of cephalostatin 1-treated cells. 
Cells were incubated with cephalostatin 1 (1 µM) or etoposide (25 µg/ml) for the indicated time 
-1 (0.25 µg/ml). A, representative 
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periods and subsequently loaded with the fluorochrome JC
microscopic pictures of a cephalostatin 1 time course experiment. B, cells showing 
predominantly green fluorescence were quantified by FACS analysis as described under 
Materials & Methods. All experiments were performed three times with consistent results. Data 
points indicate mean ± SE. * p < 0.05, *** p < 0.001 (ANOVA / Dunnett).  
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3.3.3 Activation of caspase-9 
The initiator caspase activated by the mitochondrial pathway is caspase-9. 
Since cephalostatin 1 leads to a breakdown of the electrochemical gradient 
across the inner membrane it is likely that caspase-9 is activated in the course 
of cephalostatin 1-induced apoptosis. Indeed, cephalostatin 1 (1 µM) induces 
caspase-9 activation after 4 h as shown in Figure 25. Compared to the 
activation of caspase-8, caspase-9 cleavage is triggered earlier suggesting that 
it might act upstream of caspase-8. 
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Figure 25: Activation of caspase-9 by cephalostatin 1. 
Caspase-9 cleavage after incubation with cephalostatin 1 (1 µM, 0 – 24 h) to the p35 and p37 
cleavage products. One representative Western blot out of three is shown. 
3.3.4  Release of apoptogenic factors from the intermembrane space 
Mitochondria harbour several factors contributing either to DNA fragmentation 
or activation of caspases which are released into the cytosol upon diverse 
stimuli. Among the latter, in most models, cytochrome c is essential for the 
formation of the apoptosome resulting in caspase-9 activation. In , 
Western blots of the cytosolic and mitochondrial fractions of cell lysates after 
cephalostatin 1 stimulation (1 µM, time points as indicated) are displayed. 
Surprisingly, cephalostatin 1 does not induce the release of cytochrome c in 
contrast to the positive control etoposide (25 µg/ml, 8 h). Thus, caspase-9 is 
activated by a cytochrome c-independent mechanism. Similarly to cytochrome 
c, AIF cannot be detected in the cytosolic fraction of cephalostatin 1-treated 
Jurkat cells. In contrast, cephalostatin 1 induces a rapid and strong release of 
Smac that precedes caspase-9 activation and is not abrogated by the pan-
caspase inhibitor zVADfmk. These results suggest that the release of Smac 
proceeds independently of caspases.  
Figure 26
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Figure 26: Release of apoptogenic factors from the intermembrane space. 
Cells were treated with cephalostatin 1 (1 µM) for the indicated times or with etoposide  
(25 µg/ml) as positive control. Cytosolic and mitochondrial fractions were prepared as described 
under Materials & Methods. A, B, neither cytochrome c nor AIF were released upon 
cephalostatin 1 treatment. C, cells were pretreated with zVADfmk (25 µM, 1 h) where indicated. 
Smac release is not inhibited by the pretreatment. Representative Western blots of three 
independent experiments are shown. 
In order to corroborate the Western blot results, the release of cytochrome c, 
AIF and Smac was investigated by confocal laser scanning microscopy (see 
III.6.3). In untreated cells, all three proteins co-localise in a punctuated pattern 
representing the mitochondria (Figure 27). After stimulation with cephalostatin 1 
(1 µM, 8 h), the release of Smac is visible as diffuse staining while cytochrome c 
is distinctly detected only in the mitochondria. Etoposide (25 µg/ml, 8 h), in 
contrast, induces the transfer of both cytochrome c and Smac into the cytosol. 
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AIF, however, was not released upon cephalostatin 1 treatment and only to a 
small extent in response to etoposide. 
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Figure 27: Detection of released mitochondrial factors by confocal laser scanning 
microscopy.  
Cells were either left untreated or stimulated with cephalostatin 1 (1 µM) or etoposide (25 µg/ml) 
for 8 h and prepared for confocal laser scanning microscopy as described under Materials & 
Methods. Representative figures are shown. Cyt-c, cytochrome c. 
Smac acts by sequestering inhibitors of active caspases (see II.5.3.2). In order 
to clarify whether Smac fulfils this function in cephalostatin 1-triggered 
apoptosis, immunoprecipitation experiments were performed. After treatment 
with cephalostatin 1 (1 µM) or etoposide (25 µg/ml) for 4 h, Smac and caspase-
9 were immunoprecipitated and the resulting complexes were analysed for the 
presence of XIAP (x-linked inhibitor of apoptosis) for which Smac displays the 
highest affinity among the IAP family. In untreated cells, XIAP is bound to 
caspase-9 thus inhibiting its activity (Figure 28 A). On stimulation with 
cephalostatin 1, however, XIAP is displaced from caspase-9 and becomes 
associated with Smac (Figure 28 B). This suggests that Smac released by 
cephalostatin 1 aids in the activation of caspase-9. 
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Figure 28: Immunoprecipitation of Smac and caspase-9. 
Cells were stimulated with cephalostatin 1 (1µM) or etoposide (E, 25µg/ml) for 4 h. A, lysates 
were immunoprecipitated (IP) with anti-caspase-9 antibody and analysed by immunoblotting 
(IB) with anti-XIAP antibody (upper panel) or anti-caspase-9 antibody (bottom panel). B, lysates 
were immunoprecipitated (IP) with anti-Smac antibody, followed by immunoblotting (IB) with 
anti-XIAP (top panel) or anti-Smac antibody (lower panel). All experiments were performed 
three times with analogous results. Representative Western blots are shown. 
3.3.5 Formation of an apoptosome 
Formation of the apoptosome usually requires cytochrome c derived from the 
mitochondria, the cytosolic factor Apaf-1, ATP and pro-caspase-9 (see II.5.3). 
However, some studies have shown that caspase-9 can be activated 
independently of cytochrome c [101-103] although in part of these cases, it is 
not clear whether an alternative form of apoptosome is required, whether the 
assembly of the apoptosome parts is possible without cytochrome c at all or if 
caspase-9 is activated completely without apoptosome formation. Therefore, it 
was tested, if caspase-9 activation by cephalostatin 1 treatment involves an 
association of caspase-9 with Apaf-1. 
 
Jurkat cells were incubated with cephalostatin 1 (1 h) or etoposide (25 µg/ml) 
for 4 h. Immunoprecipitates of caspase-9 were analysed for association of Apaf-
1 which would indicate that caspase-9 is recruited into an apoptosome. 
 demonstrates that cephalostatin 1 does not induce a binding between 
caspase-9 and Apaf-1 whereas in cells treated with the positive control 
etoposide, as expected, Apaf-1 associates with caspase-9. This finding together 
with the fact that cytochrome c is not released affirms the conclusion that 
Figure 
29
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caspase-9 is not activated by an apoptosome in cephalostatin 1-induced 
apoptosis.  
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Figure 29: Immunoprecipitation of caspase-9: detection of Apaf-1 binding. 
Cells were stimulated with cephalostatin 1 (1µM) or etoposide (E, 25µg/ml) for the indicated 
time, and lysates were immunoprecipitated (IP) with anti-caspase-9 antibody, followed by 
immunoblotting (IB) with anti-Apaf-1 (top panel) or anti-caspase-9 antibody (lower panel). A 
representative western blot out of three is shown. 
3.3.6 Necessity of caspase-9 for cephalostatin 1-induces apoptosis 
The results suggesting that no apoptosome formation occurs upon 
cephalostatin 1 treatment brings forth the question how caspase-9 is activated. 
It has been shown that caspase-9 can be activated by other initiator caspases 
such as caspase-8 and caspase-12 [79;102]. Thus, caspase-9 might not act as 
primary initiator caspase in cephalostatin 1-induced apoptosis and merely 
provide an enhancement to the apoptotic signalling.  
 
In order to prove whether caspase-9 is activated as topmost caspase in the 
cascade, cells were pretreated with the caspase-9 inhibitor zLEHDfmk (50 µM) 
followed by cephalostatin 1 (1 µM, 16 h) or etoposide (25 µg/ml) stimulation and 
subsequently analysed apoptosis induction. In addition, caspase-3 activity was 
measured to investigate if caspase-9 acts upstream of caspase-3. As depicted 
in Figure 30, the caspase-3 activity induced by both drugs was abrogated by the 
caspase-9 inhibitor indicating that caspase-3 is indeed activated by caspase-9. 
In contrast, pretreatment with the inhibitor led to an inhibition of etoposide-
induced apoptosis but only to a slight decrease in apoptosis mediated by 
cephalostatin 1. This indicates that caspase-9 contributes to but is not essential 
for cephalostatin 1-triggered apoptosis. 
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Figure 30: Necessity of caspase-9. 
Cells were either left untreated (CO) or activated with cephalostatin (CPH, 1 µM) or etoposide 
(ETO, 25 µg/ml) in the absence or presence of the caspase-9 inhibitor zLEHDfmk (50 µM, 1 h 
pretreatment) for 16 h. Then caspase-3 activity (A) or apoptosis (B) was quantified as indicated 
in Materials & Methods. Bars represent the mean ± SE of three independent experiments 
performed in triplicate. *** p < 0.001 (ANOVA/Dunnett). 
3.3.7 Overexpression of anti-apoptotic proteins Bcl-2 and Bcl-xL 
The anti-apoptotic Bcl-2 family members Bcl-2 and Bcl-xL are potent inhibitors 
of the mitochondrial apoptotic pathway (see II.5.3.1). In addition, both are 
localised to the ER membranes where they are also able to exert their anti-
apoptotic function.  
 
In order to investigate if the two anti-apoptotic proteins have an impact on 
cephalostatin 1-mediated apoptosis, Jurkat cells overexpressing Bcl-2 
(Jurkat/bcl-2) or Bcl-xL (Jurkat/bcl-xL) and their control cells (Jurkat/2neo or 
Jurkat/xLneo respectively) were stimulated with cephalostatin 1 (1 µM) for 
different periods of time. A Western blot analysis was carried out to verify that 
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the expression levels of Bcl-2 or Bcl-xL respectively indeed differ from control 
cells ( ).  Figure 31
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Figure 31: Influence of overexpression of Bcl-2 and Bcl-xL on cephalostatin 1-mediated 
apoposis. 
A, Control cells (Jurkat/2neo) and cells overexpressing Bcl-2 (Jurkat/bcl-2) were stimulated with 
cephalostatin 1 (1 µM) for the indicated periods of time, stained with PI and analysed by flow 
cytometry for apoptosis (upper panel). Cell lysates of Jurkat/neo and Jurkat/bcl-2 were analysed 
for Bcl-2 expression by Western blot analysis (lower panel). B, Control cells (Jurkat/xLneo) and 
cells overexpressing Bcl-xL (Jurkat/bcl-xL) were treated and analysed as described in A. A – B, 
Data are the mean ± SE of three independent experiments performed in triplicate. *, p < 0.05, 
*** p < 0.001 (ANOVA/Dunnett), compared to untreated cells. 
As shown in Figure 31 A, overexpression of Bcl-xL delayed the onset of 
cephalostatin 1-induced apoptosis. The first significant apoptosis in Jurkat/bcl-xL 
cells was not detected until 24 h after treatment whereas Jurkat/xLneo cells 
already showed considerable apoptosis levels 8 h after stimulation with 
cephalostatin 1.  
 
Bcl-2, however, was not as effective in counteracting the apoptotic signalling of 
cephalostatin 1 (Figure 31 B). Jurkat/bcl-2 cells were affected to a lower extent 
compared to their control cells but the protection was incomplete. As in 
Jurkat/2neo cells, cephalostatin 1 induced significant apoptosis levels after 8 h. 
These results suggest that cephalostatin 1 disposes is able to attenuate Bcl-2 
anti-apoptotic function. Experiments concerning the signalling leading to Bcl-2 
inactivation are presented in 3.3.8. 
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In order to elucidate if Bcl-xL inhibits cephalostatin 1-triggered apoptosis on the 
mitochondrial level, Jurkat/xLneo and Jurkat/bcl-xL cells were incubated with 
cephalostatin 1 (1 µM, 0 – 24 h). Subsequently, the release of Smac and 
dissipation of ∆ψm were determined. As depicted in  A, corresponding 
to the delayed onset of apoptosis, Smac is released later in the time course of 
cephalostatin 1 treatment in Jurkat/Bcl-x
Figure 32
L cells compared to Jurkat/xLneo (16 h 
versus 2 h). Thus, Bcl-xL exerts its protective role at least partially on the 
mitochondrial membranes. Of note, mitochondrial membrane permeabilisation 
occurred indifferent from Bcl-xL expression levels (Figure 32 B) suggesting that 
dissipation of ∆ψm is only a consecutive event in cephalostatin 1-induced 
apoptosis.  
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Figure 32: Impact of Bcl-xL overexpression on cephalostatin 1-induced Smac release and 
membrane permeabilisation. 
A, Jurkat/xLneo (upper panel) and Jurkat/bcl-xL, (lower panel) were treated with cephalostatin 1 
(1 µM) for the indicated time or as positive control with etoposide (E, 25 µg/ml, 16 h). Cytosolic 
and mitochondrial protein was prepared as described under Materials & Methods and 
Smac/DIABLO detected by a specific antibody using western blot analysis. A representative 
western blot is shown. B, Jurkat/neo and Jurkat/bcl-xL cells were incubated with cephalostatin 1 
(1 µM) for the indicated time. Apoptotis was quantified by flow cytometry. C, Cells treated as in 
B were loaded with the fluorochrome JC-1 (0.25 µg/ml). Cells showing predominantly green 
fluorescence were quantified by FACS analysis. Data points and bars represent the mean ± SE 
of three independent experiments performed in triplicate. * p < 0.05, *** p < 0.001 
(ANOVA/Dunnett). 
3.3.8 Inactivation of Bcl-2 
Mechanism of Bcl-2 inactivation 
Since Jurkat cells overexpressing Bcl-2 are only partially protected against 
cephalostatin 1, the next focus lay on the signalling pathway leading to a 
decreased anti-apoptotic effect of Bcl-2. Several mechanisms for Bcl-2 
inactivation have been proposed including cleavage of Bcl-2 mRNA or protein 
and hyperphosphorylation at Thr69 and Ser87.  
 
To elucidate which mechanism applies for cephalostatin 1, Jurkat/bcl-2 cells 
were left untreated or stimulated with cephalostatin 1 (1 µM) for different time 
periods and analysed for Bcl-2 hyperphosphorylation via Western blot analysis.  
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Figure 33: Time course of hyperphosphorylation of Bcl-2. 
Jurkat/bcl-2 cells were incubated with 1 µM cephalostatin 1 for 2 – 24 h or as positive control 
with etoposide (E, 25 µg/ml, 16 h). Cell lysates were analysed by Western blotting for 
hyperphosphorylated Bcl-2 (ppBcl-2) (A) and total unphosphorylated Bcl-2 (B). 
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As depicted in Figure 33 A, Bcl-2 is indeed hyperphosphorylated 8 h after 
cephalostatin 1 treatment indicated by the appearance of an additional band at 
28 kDa. Etoposide (E; 10 µM, 16 h) used as control showed no effect. To 
exclude that Bcl-2 levels are changed by cephalostatin 1, cell lysates were 
tested for the total Bcl-2 levels.  B demonstrates that the overall 
amount of Bcl-2 remained unchanged during the time course of cephalostatin 1 
treatment. The data suggest that cephalostatin 1 disables Bcl-2 solely by 
hyperphosphorylation. 
Figure 33
 
In order to confirm the theory that the observed Bcl-2 hyperphosphorylation is 
indeed the mechanism of Bcl-2 inactivation Jurkat cells overexpressing a 
mutant form of Bcl-2 were employed. In this mutant Bcl-2 protein, all three 
phosphorylation sites (Thr69, Ser70, Ser87) are substituted by alanine to prevent 
phosphorylation and thus inactivation of Bcl-2. In comparison to cells carrying 
the vector alone (Jurkat/2neo) and cells overexpressing the wildtype Bcl-2 
protein (Jurkat/bcl-2), the mutant cell line (Jurkat/mbl-2) was completely 
protected against cephalostatin 1 (Figure 34 A). To prove that all three cell lines 
responded as they are reported to, they were exposed to taxol (1 µM, 24 h). 
 B shows that the Jurkat/mbcl-2 cells were better protected against 
taxol-induced apoptosis than cells overexpressing the wild-type Bcl-2 protein 
while Jurkat/neo cells succumbed freely to apoptosis. 
Figure 34
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Figure 34: Apoptosis induction by cephalostatin 1 in cells overexpressing wildtype or 
mutated Bcl-2. 
Control cells (Jurkat/2neo), cells overexpressing wildtype Bcl-2 (Jurkat/bcl-2) or Bcl-2 with 
alanine-substituted phosphorylation sites (Thr69, Ser70, Ser87) (Jurkat/mbcl-2) were stimulated 
with cephalostatin 1 (1 µM) for the indicated periods of time (A) or with taxol (1 µM, 24 h) (B). 
Apoptotic cells were quantified by flow cytometry. Data are the mean ± SE of three independent 
experiments performed in triplicate. *** p < 0.001 (ANOVA/Dunnett). 
Mediator of Bcl-2 hyperphosphorylation 
Of interest was further which kinase may be responsible for the cephalostatin 1-
induced Bcl-2 hyperphosphorylation. Via Western blot analysis, the activation of 
JNK upon cephalostatin 1 stimulation was investigated in Jurkat cells. As 
depicted in Figure 35 A, both JNK1 and JNK2 were phosphorylated and thus 
activated already 2 h after cephalostatin 1 treatment and phosphorylation 
increased up to 8 h after stimulation. In order to establish a link between JNK 
activation and Bcl-2 hyperphosphorylation, Jurkat cells were pre-treated with 
the specific JNK inhibitor SP600125.  B reveals that the inhibitor Figure 35
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abolishes Bcl-2 hyperphosphorylation after treatment with cephalostatin 1 as 
well as with taxol.  
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Figure 35: Involvement of JNK in cephalostatin 1-induced Bcl-2 hyperphosphorylation. 
A, Jurkat/bcl-2 cells were stimulated with cephalostatin 1 (1 µM) for the indicated periods of 
time. Etoposide (E, 25 µg/ml, 8 h) was used as positive control. Cell lysates were analysed with 
anti-phospho-JNK antibody for the activated forms of JNK1 (p46) and JNK2 (p54). B, Cells were 
incubated with (+) or without (-) SP600125 (10 µM) for 1 h and further stimulated with 
cephalostatin 1 (1 µM) or taxol (1 µM) for 16 h. Lysates were immunoblotted with anti-phospho-
Bcl-2 antibody. C, Jurkat/neo, Jurkat/bcl-2 and Jurkat/mbcl-2 were left untreated, treated with 
cephalostatin 1 (1 µM) or taxol (1 µM) for 24 h (as described in  A and B). The diagram 
shows the percentage of apoptotic cells at 24 h of Jurkat/bcl-2 and Jurkat/mbcl-2 compared to 
Jurkat/neo cells (= 100%). 
Figure 34
Of note, taxol seems to lead to a stronger hyperphosphorylation than 
cephalostatin 1. To clarify whether this difference in Bcl-2 hyperphosphorylation 
has an impact on Bcl-2 inactivation, the levels of apoptosis induced by these 
two drugs in Jurkat/neo, Jurkat/bcl-2 and Jurkat/mbcl-2 cells were compared as 
shown in Figure 35 C. As expected, Bcl-2 overexpressing cells are more 
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sensitive to taxol than to cephalostatin 1 suggesting that the stronger 
hyperphosphorylation induced by taxol leads indeed to a stronger inactivation of 
Bcl-2. However, Jurkat/mbcl-2 cells also showed a higher sensitivity towards 
taxol compared to cephalostatin 1 which implies an additional mechanism to 
inactivate Bcl-2. 
Signalling upstream of JNK activation and Bcl-2 hyperphosphorylation 
It is widely accepted that JNK is an important player in the cellular stress 
response to a wide variety of stimuli. The majority of compounds reported to 
induce Bcl-2 hyperphosphorylation activate JNK and induce a cell cycle arrest 
in M-phase, as e.g. microtubule-damaging agents [104].  
 
In order to investigate whether cephalostatin 1-induced JNK activation and 
successive Bcl-2 hyperphosphorylation depend on an M-phase arrest, the cell 
cycle distribution of untreated Jurkat cells and cells incubated with cephalostatin 
1 (1 µM) or taxol (1 µM) for 8 h was investigated. The time point was chosen 
due to evident JNK activation (see  A). As demonstrated by Figure 36, 
taxol induces a potent M-phase block whereas cephalostatin 1 did not interfere 
with cell cycle progression. Interestingly, cells in G
Figure 35
1 and S-phase seem to be 
more susceptible to cephalostatin 1 since the overall percentage of cells in G1- 
and S-phase decreased after cephalostatin 1 stimulation. The appearance of a 
sub-G1 peak, (Figure 36, middle panel) reveals that cells formerly present in G1 
and S underwent apoptosis. The percentage of cells in the G2/M-phase was not 
altered after cephalostatin 1 treatment compared to control. These results 
indicate that both JNK activation and Bcl-2 phosphorylation induced by 
cephalostatin 1 occur independent of M-phase blockade. 
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Figure 36: Cell cycle analysis of cephalostatin 1 and taxol-treated cells. 
A, Jurkat cells were incubated with cephalostatin 1 (1 µM) or taxol (1 µM) for 8 h, stained with PI 
and analysed by FACS. The histograms show the distribution of cells according to their DNA 
content. Cell cycle phases are marked by arrows. B, Quantification of cells in G0/G1, S and 
G2/M-phase. The data shown are the mean ± SE of three independent experiments performed 
in triplicate. 
Many genotoxic agents mediate JNK activation [105] and some have been 
described to phosphorylate Bcl-2 [106]. To elucidate whether cephalostatin 1 
leads to DNA lesions, Jurkat cells treated with cephalostatin 1 (1 µM) or 
etoposide (10 µM) for 4 h were subjected to a comet assay (see III.10). Both 
drugs induced comparable levels of apoptosis at these concentrations (data not 
shown). Figure 37 provides clear evidence that etoposide induces DNA damage 
visible as the typical comet tail whereas cephalostatin 1 does not. This 
experiment suggests that DNA damage is not the type of cell stress leading to 
cephalostatin 1-induced JNK activation. 
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Figure 37: Comet assay of cells stimulated with etoposide and cephalostatin 1. 
Jurkat cells were either left untreated (CO) , stimulated with cephalostatin 1 (CPH-1; 1 µM) or 
etoposide (10 µM) for 4 h. DNA damage analysis was performed by comet assay as described 
under Materials & Methods. Representative pictures of three independent experiments are 
shown. 
3.4 INVOLVEMENT OF THE ENDOPLASMIC RETICULUM 
Endoplasmic reticulum stress (ER stress) provides another model for the 
activation of caspase-9.  
3.4.1 Cephalostatin 1 elicits ER stress 
As illustrated in II.5.4, the UPR induces upregulation of the chaperone BiP and 
the transcription factor CHOP which may serve as marker for the induction of 
ER stress. Cephalostatin 1 induces rapid upregulation of BiP after 2 h (
, A) which is enhanced persistently throughout the stimulation period. In 
accordance, CHOP transcription is also increased after 2 h (Figure 38, B). 
CHOP levels, however, fall below control level after 8 h of stimulation. As 
positive control, cells were stimulated with tunicamycin (T, 1 µg/ml), an 
established inducer of ER stress which inhibits protein glycosylation inside the 
ER lumen [107]. 
Figure 
38
 
These results show clearly that cephalostatin 1 induces ER stress. The process 
precedes activation of caspase-9 indicating that ER stress is triggered upstream 
of caspase-9. Compared to the time course of Smac release which is released 
after 2 h, upregulation of ER stress markers happens in parallel. This suggests 
that cephalostatin 1 targets different cellular organelles equivalently. 
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Figure 38: Induction of ER stress marker proteins by cephalostatin 1. 
Cells were incubated with 1 µM cephalostatin 1 for 0 – 24 h or tunicamycin (1 µg/ml) for  
16 h (A) / 3 h (B) and analysed by Western blotting for the chaperone BiP (A) and the 
transcription factor CHOP (B). One representative Western blot out of three is shown. 
3.4.2 Activation of caspase-12 
Since cephalostatin 1 induces ER stress, it is conceivable that it also endues 
caspase-12 activation. To date, an antibody against the active fragments of 
caspase-12 is not available but the decrease of the zymogen form after 2 h 
which continues until 16 h when virtually no pro-caspase-12 is detectable 
indicates that cephalostatin 1 potently induces the activation of caspase-12.  
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Figure 39: Activation of caspase-12 by cephalostatin 1 treatment. 
Caspase-12 cleavage indicating activation after incubation with cephalostatin 1 (1 µM, 0 – 24 h) 
or tunicamycin (1 µg/ml, 8 h). One representative Western blot out of three is shown. 
The early cleavage of the caspase-12 zymogen is correlated with the time 
course of ER stress (cf. Figure 38). As mentioned above, ER stress as well as 
activation of caspase-12 are detectable before caspase-9 activation. This 
suggests that caspase-12 might be the primary initiator caspase in 
cephalostatin 1-induced apoptosis. In addition, caspase-9 is obviously activated 
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downstream of caspase-12 and might act in the amplification of apoptosis 
induction. 
 
Activation of caspase-12 is mediated by diverse mechanisms depending on the 
cell model (see II.5.4). For cephalostatin 1-induced apoptosis, the activation of 
caspase-7 and calpain, two potential triggers for caspase-12, was investigated.  
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Figure 40: Activation of caspase-7 and calpain by cephalostatin 1. 
Figure 40
Cells were stimulated with cephalostatin 1 (1 µM) for the indicated times and subsequently 
analysed by Western blotting for cleavage of caspase-7 to the cleavage product p20 (A) and for 
cleavage of calpain to the active form (p76, B). Etoposide (E, 10 µM, 16 h) or A23187 (A, 1 µM, 
16 h) were used as positive controls. All experiments were performed three times with 
consistent results. One representative Western blot is shown. 
Removal of the prodomain of pro-caspase-7 (35 kDa) produces a 32 KDa 
intermediate which is further cleaved into the active subunits. The large subunit 
of active caspase-7 ( , A, p20) appeared at 2 h of treatment with futher 
increase over the course of stimulation. Calpain which is autolytically activated 
in the presence of free Ca is notably activated after 1 h. Etoposide (E, 10 µM) 
and A23187 (A, a calcium ionophore shown to activate calpain [108], 1 µM) 
were used as positive controls. Both enzymes are activated early in the time 
course. However, at 2 h, when a clear activation of caspase-12 was 
determined, activation of caspase-7 appears modest in comparison to the levels 
of active calpain. 
 
 
 
 
V. DISCUSSION 
Cancer is the second leading cause of death in the western countries. Although 
great improvements in cancer treatment have been achieved over the last 
decades, in many cases patients still lose the fight against this dreaded 
disease. Due to the vast diversity in marine life offering opportunities for the 
search for new remedies, intense interest in bioactive marine compounds has 
evolved. These substances might prove as invaluable new chemotherapeutics.  
 
This work provides insight into the remarkable cytotoxic activity of  
cephalostatin 1, a compound isolated from the marine worm Cephalodiscus 
gilchristi Ridewood by the team of Dr. G.R. Pettit [1].  
CHARACTERISATION OF THE CELL DEATH INDUCED BY CEPHALOSTATIN 1 
Cephalostatin 1 exhibits a cytotoxic activity at remarkably low concentrations in 
the MTT assay (significance reached at 0.1 nM) against Jurkat T cells. The IC50 
was calculated as 1.25 nM which correlates well with the GI50 obtained from the 
NCI-60 panel (1 nM) [2].  
 
Apoptotic cell death includes several defined biochemical alterations which can 
be employed for defining the type of cell death triggered by cephalostatin 1. 
Light microscopic analyses revealed the formation of apoptotic bodies. Usually, 
shedding of apoptotic fragments is accompanied by a condensation of the cell. 
A flow cytometry measurement of cell size and granularity clearly demonstrates 
that cephalostatin 1 leads to cell shrinkage and increased granularity. Evidence 
for apoptosis induction by cephalostatin 1 is also provided by DNA staining 
displaying the appearance of condensed chromatin and DNA fragments over 
the course of stimulation. Quantitative analysis of DNA fragmentation via FACS 
showed a time- and dose-dependent induction of apoptosis. In addition, flow 
cytometry was used for the detection of phosphatidylserine exposure which 
occurred after 8 h of stimulation with cephalostatin 1.  
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SIGNAL TRANSDUCTION PATHWAYS IN CEPHALOSTATIN 1-INDUCED 
APOPTOSIS 
Apoptotic changes resulting finally in the demise of the cell are commonly 
mediated by the caspase family that act as initiators as well as executors of the 
apoptotic cascade. Increasing numbers of recent studies, however, present 
models for caspase-independent apoptosis. These pathways are mediated by 
calpains [3;4], cathepsins [5-7], AIF [8-13] or Bax [14-16]. In this study, caspase 
activation was evidenced by Western blot analysis of cleavage products of 
caspase-3, -7, -8, -9 and -12. Indeed, cephalostatin 1-induced apoptosis is 
dependent on caspases as shown by abrogation of apoptosis after inhibition 
with the pan-caspase inhibitor zVADfmk. In spite of the prevention of 
cephalostatin 1-triggered apoptosis by zVADfmk, the initiation of the signal 
pathway may be performed by a mechanism different from the common 
caspase activation pathways. 
 
So far, three pathways of apoptosis induction have been proposed: one 
employing death receptors on the cell membrane, another involving 
mitochondrial activation and the third emanating from the endoplasmic 
reticulum. In the following will be discussed which pathways are involved in 
cephalostatin 1-triggered apoptosis. 
1.1 INVOLVEMENT OF CD95 PATHWAY 
The extrinsic pathway induced by activation of death receptors implies 
activation of caspase-8 as initiator caspase after assembly of the DISC. 
 
Initially, upregulation of death receptor ligands observed upon treatment with 
anticancer drugs was regarded as crucial apoptosis-inducing mechanism of 
chemotherapeutic drugs. Thereafter, numerous studies have provided evidence 
against this theory and currently it is accepted that anticancer drugs primarily 
utilize mitochondrial signals, i.e. caspase-9 activated in the apoptosome 
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although a contribution of the death receptor system can not be completely 
excluded in some cases [17].  
In this regard, cephalostatin 1 acts like a typical chemotherapeutic agent in that 
apoptosis induced by cephalostatin 1 does not require death receptor signalling. 
This was shown by CD95 deficient Jurkat cells which were killed equally to their 
controls. The possibility that another death receptor might be involved in the 
pathway was ruled out with caspase-8-/- cells which also underwent apoptosis 
indiscriminately from control cells. In addition, although caspase-8 was 
activated by cephalostatin 1 it occurred at a very late time point (16 h) indicating 
that caspase-8 is not activated as initiator caspase. More likely, cleavage of 
caspase-8 occurs by caspase-3 in the wake of the caspase cascade as shown 
for several anticancer drugs [18;19] leading to an amplification loop for 
apoptosis. 
1.2 INVOLVEMENT OF MITOCHONDRIA IN CEPHALOSTATIN 1-INDUCED 
APOPTOSIS 
As mentioned above, the mitochondria are key mediators for the apoptotic 
process triggered by anticancer agents. Apoptogenic factors released from the 
intermembrane space (IMS) account for the activation of caspase-9 
(cytochrome c and Smac) while others mediate caspase-independent apoptosis 
(AIF, EndoG).  
 
The release mechanism of proteins present in the IMS has been the focus of 
intense studies and there is still much controversy on how the pore is composed 
and regulated. The oldest model implies the ANT on the IMM and the VDAC on 
the OMM (see Figure 41). Opening would be accompanied by loss of 
membrane potential, swelling of the matrix and finally rupture of the OMM 
releasing the intermembrane proteins into the cytosol [20]. The pro-apoptotic 
Bcl-2 family members Bax and Bak were shown to internalise into the OMM and 
form tetrameric channels enabling proteins to leak out of the IMS [21;22]. 
Recent studies provide evidence that the transition pore consists of more than 
the two components mentioned before. In addition, distinct opening modes have 
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been discussed depending on the Ca2+ concentration in the mitochondrial 
matrix [23]. In spite of the prevailing disaccord on the pore assembly, most 
agree that mitochondrial matrix swelling and dissipation of ∆ψm occur in 
accordance with mitochondrial dysfunction resulting ultimately in apoptosis.  
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Figure 41: Proposed models of the release of proteins from the mitochondrial IMS. 
An apoptotic signal induces opening of the permeability transition pore (PTP) consisting, among 
others, of VDAC (voltage-dependent anion channel), ANT (adenine nucleotide translocator) and 
Cyp-D (cyclophilin D) on the matrix side. Another model suggests the involvement of Bax which 
undergoes a conformational change upon an apoptotic signal and interacts with components of 
the PTP inducing an opening of the PTP. In addition, Bax and Bak were shown to form 
tetrameric channels in the OMM. 
Cephalostatin 1-induced loss of mitochondrial membrane potential was 
detected by JC-1 staining. Analysis of the ultrastructural alterations of Jurkat 
cells upon stimulation with cephalostatin 1 revealed obvious dilatations of 
nuclear and ER membranes and fragmented nuclei. Most strikingly, the 
mitochondria were not enlarged as would be expected. Mitochondrial size was 
markedly reduced and the matrix seemed to be condensed. In contrast, the 
cristae appeared swollen. A recent publication also describes the condensation 
of mitochondrial matrix and cristal unfolding in an early phase of growth factor 
withdrawal which is supposed to facilitate the release of cytochrome c thus 
V Discussion  87 
triggering the caspase cascade [24]. This could apply for cephalostatin 1-
induced apoptosis as well but the effect was observed at a late time point (16 h) 
contradicting the function of matrix condensation in apoptosis initiation. In 
addition, no cytochrome c release from the mitochondria was detected after 
cephalostatin 1 treatment. Thus, mitochondrial dysfunction initiated by 
cephalostatin 1 seems to occur in a previously unknown manner.  
 
The observed mitochondrial dysfunction indicates an involvement of 
mitochondria in cephalostatin 1-mediated apoptosis. The common execution 
pathway emanating from the mitochondria involves the formation of the 
apoptosome consisting of cytochrome c from the IMS, the cytosolic protein 
Apaf-1 and pro-caspase-9. Indeed, caspase-9, the initiator caspase of the 
intrinsic pathway, was activated after 4 h. Activation occurred previous to 
caspase-8 cleavage suggesting that caspase-9 acts upstream in the initiation 
cascade.  
Analysis of the release of apoptogenic factors into the cytosol, though, 
demonstrated that only Smac escaped from the IMS in contrast to cytochrome c 
and AIF which could not be detected in the cytosolic fraction. Therefore, 
activation of caspase-9 proceeds in a cytochrome c-independent mechanism. 
Cytochrome c-independent activation of caspase-9 has been shown for a TNFα 
model and several ER stress models [25-27]. In classical apoptosis, 
apoptosome formation involves cytochrome c thus, most probably, cytochrome 
c-independent activation of caspase-9 does not require Apaf-1 or a functional 
apoptosome. In line with this theory, cephalostatin 1-induced caspase-9 
activation does not imply association of caspase-9 with Apaf-1.  
 
In stress-induced apoptosis, Smac is released from mitochondria where it 
interacts predominantly with the caspase inhibitor XIAP in a manner that 
displaces caspases from XIAP [28]. Smac released by cephalostatin 1 fulfils this 
function by sequestering XIAP previously bound to caspase-9 thus fostering 
caspase-9 activation. Since Smac is selectively released from the mitochondria 
it obviously acts as main mitochondrial signalling molecule. This emphasizes 
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the uniqueness of the cephalostatin 1 signalling pathway since most other 
studies show that release of cytochrome c into the cytosol also implies Smac 
release which sometimes even occurs in tandem [29].  
 
Interestingly, the release of Smac by cephalostatin 1 proceeds in a caspase-
independent manner as its onset happened before caspase-9 activation and 
release was not affected by preincubation with the pan-caspase inhibitor 
zVADfmk. This observation stands in contrast to a recent study in which the 
release of Smac is a secondary event following cytochrome c release and 
caspase activation [30]. As a result, the caspase-independent release of Smac 
suggests that caspase activation upstream of the mitochondria is not required 
for cephalostatin 1-induced apoptosis. The signalling resulting in Smac release 
has not been identified yet but it is conceivable that JNK which is activated early 
in cephalostatin 1-induced apoptosis plays a role in Smac release as recently 
proposed [31]. Backing this theory is the very recent work of another group who 
showed that JNK produces a distinct Bid cleavage product in TNFα-induced 
apoptosis (jBid) which is able to induce selective Smac release without 
concomitant cytochrome c leakage [32]. The question how the selective release 
of Smac is mediated is still unanswered. Truncated Bid has been shown to 
induce a conformational change of Bax and Bak whereupon these trigger the 
release of proteins from the IMS. Obviously, jBid effects Smac release in a 
different manner since concomitant cytochrome c release was not detected. It is 
conceivable that different cleavage products of Bid lead to another form of 
conformational change in Bax and Bak which might result in different pore 
formation. Calpain has also been shown to cleave Bid at sites differing from 
those commonly described [33]. Beyond that, calpain can cleave Bax to 
produce an even more potent pro-apoptotic protein than wtBax [34]. Calpain 
activated by cephalostatin 1 might mediate the selective Smac release via an 
altered Bax / Bak signalling. Another model might include an interaction of 
cephalostatin 1 with the components of the permeability transition pore possibly 
leading to an opening of the PTP. Since Smac is a soluble protein within the 
IMS in contrast to cytochrome c and AIF that are attached to the inner 
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membrane [35;36], the selective release of Smac might be facilitated while 
cytochrome c and AIF are retained.  
 
The hypothesis that caspase activity is not required upstream of the 
mitochondria raises the question if the release of Smac is required for caspase-
9 activation. Recent publications propose that under certain conditions, Smac 
may be sufficient to initiate a caspase-9-dependent apoptotic pathway in the 
absence of cytochrome c and apoptosome formation [37;38]. However, 
regarding the data that inhibition of caspase-9 did not lead to a complete 
inhibition of cephalostatin 1-mediated apoptosis and taking into account that 
caspase-9, that is not complexed by Apaf-1, displays a markedly decreased 
activity [39] leads to the assumption that the common mitochondrial execution 
pathway routed via caspase-9 may not be the essential initiator of the 
cephalostatin 1-induced caspase cascade.  
The finding, that overexpression of Bcl-xL delays both apoptosis and Smac 
release, indicates that Smac is pivotally involved in cephalostatin 1-induced 
apoptosis. Although Smac displaces XIAP from caspase-9, this does not seem 
to be the crucial function of Smac since obviously – as discussed above – 
caspase-9 does not act as initiator of cephalostatin 1-mediated apoptosis. An 
explanation might be provided by the studies of Riedl et al. [40] and Chai et al. 
[41] who present evidence for the interaction of XIAP with caspase-3 and 
caspase-7. Since cephalostatin 1 triggers the activation of caspase-3 and 
caspase-7, Smac may relieve the inhibition of caspase-3 and -7 by XIAP and 
thus contribute considerably to an unchallenged apoptotic progress. Such a 
contribution was demonstrated for receptor-mediated apoptosis in type II cells. 
After binding of death ligands, these cells require a mitochondrial signal for 
complete activation of caspase-3 which was shown to be conveyed by Smac 
[42;43]. Thus, cephalostatin 1 might employ a pathway different from common 
extrinsic and intrinsic pathways which is entirely functional only in combination 
with Smac activity. 
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1.3 INVOLVEMENT OF THE ENDOPLASMIC RETICULUM 
The endoplasmic reticulum has only recently come into the focus of interest as 
major player in apoptotic processes. Several regulators of the mitochondrial 
pathway are found to be present also at ER membranes such as members of all 
three sub-groups of the Bcl-2 family [44-48]. Exclusively ER-located pro-
caspases (caspase-12 [49], caspase-8L [50]) and corresponding regulators 
such as TRAF2 [51] and BAP31 [50] were identified. The function of the ER 
lumen as Ca2+ store mark the ER as important source of apoptotic signals. 
Mobilisation of Ca2+ is sufficient for the initiation of apoptosis in some models 
[52-55]. In addition, intense crosstalk between ER and mitochondria mediated 
by Ca2+ leads to a sensitisation of the latter to pro-apoptotic signals [56]. Apart 
from agents perturbing protein glycosylation in the ER or Ca2+ homeostasis 
[55;57;58], the ER-mediated pathway has been shown to mediate several 
models of drug-induced apoptosis [59;60] and ischemia / reperfusion injury 
[61;62].  
 
ER stress can be identified by analysis of changes in the expression levels of 
distinct ER stress markers. BiP is an ER-located chaperone whose upregulation 
indicates a disturbance in protein processing in the ER lumen. CHOP, a C/EBP 
homologous transcription factor, is implied in the mediation of the apoptotic 
signal from the ER. Cephalostatin 1 induces rapid upregulation of both ER 
stress markers after 2 h indicating induction of ER stress by cephalostatin 1. In 
concert, caspase-12 which may act as initiator caspase for ER stress-induced 
apoptosis is activated markedly after 2 h. These events precede activation of 
caspase-9 giving rise to the idea that the cephalostatin 1-induced signalling 
pathway originates at the endoplasmic reticulum and that caspase-12 might act 
as primary initiator caspase activating caspase-9 downstream. Indeed, a recent 
study provided evidence of such an interaction [27]. The signal upstream of 
caspase-12 is not defined yet in cephalostatin 1-induced apoptosis but most 
probably it is mediated by calpain being activated very rapidly after 1 h as 
shown by Nakagawa et al. [63]. Caspase-7 has also been described to 
translocate to the ER and cleave caspase-12 there [64] but considering the 
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rather low signal of active caspase-7 at 2 h stimulation when caspase-12 is 
clearly activated, it is unlikely that caspase-7 acts as upstream signal.  
 
As discussed in 1.2, the mitochondria are involved and have a relevant part in 
cephalostatin 1-induced apoptosis. However, the topmost caspase of the 
cascade is most probably activated at the endoplasmic reticulum. Therefore, 
either some kind of crosstalk is initiated between the two organelles which 
coordinates downstream events or cephalostatin 1 acts on both organelles in 
parallel. In Figure 42, the time flow of events triggered by cephalostatin 1 is 
depicted. The first event triggered by cephalostatin 1 is the activation of calpain 
but since all other events were not investigated at this early time point it cannot 
be excluded that they might be induced in the same time window as calpain 
(excepting caspase-7 and caspase-9). Calpain activation at 1 h evidences a 
rapid onset of ER stress. Since calpain is a Ca2+-dependent protease located in 
the cytosol [65], an increase in cytosolic [Ca2+] will presumptively have occurred 
before. Calcium constitutes one of the mechanisms of interaction between the 
ER and mitochondria. Release of Ca2+ into the cytosol activates the Ca2+-
dependent phosphatase calcineurin which in turn dephosphorylates Bad 
resulting in its activation [66]. Subsequently, Bad can translocate to the 
mitochondria and bind to the anti-apoptotic protein Bcl-2 leading to Bcl-2 
inactivation. Another form of signalling consists in the direct transport from Ca2+ 
from the ER to the mitochondria which has been shown to sensitise the 
mitochondria for pro-apoptotic signals [67]. A third model describes a caspase 
cleavage product of BAP31 which can transfer the pro-apoptotic signal from the 
ER to the mitochondria [68]. This model, however, is unlikely for cephalostatin 
1-induced apoptosis since according to the results presented here there is no 
time difference between activation of caspase-12 and release of Smac. In 
addition, Smac release proceeds independently of caspases. These findings 
contradict the assumption that caspase activity is required for the ER-
mitochondria crosstalk.  
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The second scheme for the sequence of events in cephalostatin 1-mediated 
apoptosis assumes that Smac release as well as calpain activation and ER 
stress are triggered within the same time frame. This would imply that 
cephalostatin 1 either activates an unknown mediator that virtually immediately 
targets both ER and mitochondria or cephalostatin 1 interacts directly with the 
membranes of the two organelles, e. g. by insertion thus triggering the release 
of Ca2+. Another approach might be an interaction with proteins guarding 
membrane integrity such as Bcl-2 proteins. Considering the chemical steroid 
structure of cephalostatin 1 which displays a hydrophobic center and two 
hydrophilic moieties toward the ends of the molecule it is conceivable that it is 
able to interact with biological membranes which are also composed of a 
lipophilic core surrounded by hydrophilic layers.  
 
Cephalostatin 1
Calpain - 1 h
CHOP - 2 h
BiP - 2 h
Caspase-12 - 2 h Smac - 2 h
Caspase-9 - 4 h
Endoplasmic reticulum Mitochondria
Caspase-7 - 4 h (2 h)
 
?
?
?
Figure 42: Proposed time flow of cephalostatin 1-induced apoptosis initiation. 
Events at the ER are presented in the left panel, events at the mitochondria in the right panel. 
Question marks indicate potential interactions/activations without definite proof provided in this 
study. 
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REGULATION OF CEPHALOSTATIN 1-INDUCED APOPTOSIS 
Overexpression of Bcl-2 and Bcl-xL in cancer cells due to mutations poses a 
severe problem for cancer therapy since these cells, protected against 
mitochondrial apoptosis as well as ER-mediated apoptosis, are often resistant 
against chemotherapeutic agents which mainly employ the mitochondria as 
apoptotic mediators [69-75].  
Cephalostatin 1-induced apoptosis is inhibited by Bcl-xL overexpression. 
However, Bcl-2 overexpression did not convey complete protection against 
cephalostatin 1 indicating that cephalostatin 1 initiates an inactivation 
mechanism. 
 
Several mechanisms are reported to inactive Bcl-2: activated caspases have 
been shown to cleave Bcl-2 generating a 23 kDa pro-apoptotic product [76;77]. 
Furthermore, down-regulation of Bcl-2 mRNA or Bcl-2 protein has been 
observed after treatment with several anti-cancer drugs [78;79]. In cephalostatin 
1-induced apoptosis, total Bcl-2 levels are not altered suggesting that cleavage 
of the protein or alterations of mRNA levels do not apply here. In addition, Bcl-2 
phosphorylation has been observed as mechanism for altering the activity of the 
protein. Under physiological conditions, Bcl-2 is phosphorylated on Ser70 during 
M-phase [80] by PKC [80;81] and ERK [82]. Phosphorylation of Ser70 seems to 
be important for the anti-apoptotic function of the protein [80] whereas 
hyperphosphorylation on Thr69 and Ser87 was proposed to inactivate Bcl-2 [83] 
and abrogate its protective role by impairing its interaction with the pro-apoptotic 
protein Bax [84]. This theory, however, is discussed intensely since recently 
published data present evidence against a decrease of anti-apoptotic function 
by Bcl-2 hyperphosphorylation [85]. 
 
Hyperphosphorylation of Bcl-2 was shown to be induced by anticancer drugs, 
such as anti-mitotic agents [86] and some DNA damaging chemotherapeutics 
[87]. However, cephalostatin 1-induced Bcl-2 hyperphosphorylation occurs 
independent of a mitotic arrest or DNA-damage and is sufficient for the 
observed Bcl-2 inactivation. Compared to taxol, the degree of 
94 V Discussion  
hyperphosphorylation induced by cephalostatin 1 seemed to be lower 
corresponding to the lower sensitivity of Bcl-2 overexpressing cells towards 
cephalostatin 1. Interestingly, Jurkat T cells carrying mutated phosphorylation 
sites (Jurkat/mbcl-2) displayed a higher apoptosis rate after taxol treatment 
compared to cephalostatin 1. This observation may be explained by an 
additional inactivating mechanism of taxol, such as cleavage of Bcl-2 [88].  
Several previous studies have focused on the signalling pathway leading to Bcl-
2 hyperphosphorylation. Among the key enzymes responsible for Bcl-2 
inactivation various kinases have been described (Raf-1 [89], PKA [90], ASK 
[91], JNK [83], ) depending on cell type and stimulus. Activated JNK has been 
implied in the hyperphosphorylation of Bcl-2 in response to numerous anti-
mitotic agents such as taxol, Vinca alkaloids or cryptophycins [92]. In some 
settings, JNK activation but no Bcl-2 hyperphosphorylation was evident [93] or 
no causal link between JNK activation and Bcl-2 hyperphosphorylation could be 
proven [94]. In fact, PKA was favoured as the kinase exclusively responsible for 
Bcl-2 hyperphosphorylation [90]. Since the specific JNK inhibitor SP600125 
strongly impaired cephalostatin 1-triggered Bcl-2 hyperphosphorylation, JNK 
acts as the crucial kinase upstream of Bcl-2.  
 
How does cephalostatin 1 induce JNK activation and subsequent Bcl-2 
hyperphosphorylation? JNK/SAPK (stress-activated protein kinase) activation is 
involved in the regulation of cell cycle progression at the transition from G1- to 
S-phase [95]. JNK also fulfils functions in the M-phase [83]. Beyond that, it is 
induced by diverse extracellular stimuli such as UV irradiation, pro-inflammatory 
cytokines, heat shock and numerous cytotoxic agents [96]. Among these, 
microtubuli-interfering agents (MIA) inducing an arrest in G2/M-phase activate 
JNK as major pro-apoptotic player [92]. JNK activation by MIAs was often linked 
to Bcl-2 hyperphosphorylation suggesting that an arrest in M-phase is a crucial 
factor in the signalling pathway leading to Bcl-2 inactivation and subsequent 
apoptosis [83;97;98]. Cephalostatin 1, however, does not arrest cells in G2/M-
phase contradicting the view that an arrest in M-phase may be a prerequisite for 
JNK activation with a subsequent Bcl-2 hyperphosphorylation and inactivation.  
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JNK activation was also found in response to DNA damaging agents [99;100]. 
Some of them, such as platinum compounds and doxorubicin, were shown to 
induce Bcl-2 hyperphosphorylation [87]. So far, the pathway leading to Bcl-2 
hyperphosphorylation in DNA damage-induced apoptosis has not been 
investigated but involvement of JNK is conceivable. Cephalostatin 1, however, 
does not induce DNA damage excluding this mechanism for JNK activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI. SUMMARY AND OUTLOOK 
The present study provides insight into the cell death signalling pathway 
induced by cephalostatin 1, a marine bis-steroidal compound.  
 
Cephalostatin 1 triggers apoptosis in human Jurkat T cells.  
Apoptosis was shown by the formation of apoptotic bodies, DNA fragmentation 
and phosphatidylserine exposure. Cephalostatin 1-induced apoptosis, which 
proceeds time- and dose-dependently, is dependent on caspases. , 
 
Cephalostatin 1-induced apoptosis follows a novel pathway that is 
characterised by selective Smac release from the mitochondria and 
caspase-9 activation without apoptosome formation.  
Signalling involving death receptors and subsequent components of the 
extrinsic pathway is not required. In contrast, mitochondria are affected as 
evident in the loss of the membrane potential. Unexpectedly, the mitochondrial 
matrix does not swell but appears condensed. Although neither cytochrome c 
nor AIF are released, Smac is selectively translocated into the cytosol where it 
binds to XIAP. Thus, XIAP previously bound to caspase-9 is displaced. 
Caspase-9 does not associate with Apaf-1 and is activated without requirement 
for apoptosome formation. However, caspase-9 contributes to but is not 
essential for cephalostatin 1-induced apoptosis.  
 
Cephalostatin 1 triggers rapidly ER stress.  
ER stress is shown by upregulation of BiP and CHOP. Calpain is activated very 
early which might effect the observed activation of the ER-located caspase-12. 
 
Cephalostatin 1 is able to counterregulate the anti-apoptotic effect of  
Bcl-2.  
Overexpression of Bcl-2 confers only partial protection against cephalostatin 1. 
Inactivation of Bcl-2 is brought about by hyperphosphorylation mediated by 
JNK. The signalling upstream of JNK does involve neither an arrest in G2/M-
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phase nor DNA damage. In contrast, overexpression of the anti-apoptotic 
protein Bcl-xL abrogates cephalostatin 1-induced apoptosis.  
 
In summary, the results presented here characterise cephalostatin 1 as a 
remarkable experimental chemotherapeutic agent that induces an exceptional 
apoptotic pathway. Therefore and also due to its ability to inactivate the anti-
apoptotic protein Bcl-2, cephalostatin 1 provides good prospects to be utilised 
against chemoresistant types of cancer. Cephalostatin 1 will be tested against a 
range of chemoresistant cell lines in order to verify its usability. Further studies 
will investigate into the signalling leading to selective Smac release, to JNK 
activation and the potential links between ER and mitochondrial signalling. 
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Figure 43: Schematic illustration of the cephalostatin 1-induced signalling pathway. 
S, Smac; C, cytochrome c; CHOP, C/EBP homologous protein; BiP, binding protein; red cross: 
not involved in signalling; --| inhibition  
 
VII. APPENDIX 
1. ABBREVIATIONS 
Apaf-1 Apoptosis protein-activating factor 1 
ADP Adenosine diphosphate 
AFC Amino trifluoromethyl coumarin 
AIF Apoptosis inducing factor 
ANT Adenine nucleotide translocator 
ANOVA Analysis of variance between groups 
APS Ammonium persulfate 
AT pair Adenin – thymin pair 
ATP Adenosine triphosphate 
BAP B-cell antigen receptor-associated protein 
Bcl B-cell lymphoma 
BH Bcl-2 homology 
BiP Binding protein 
BIR Baculovirus IAP repeat 
BSA Bovine serum albumin 
CAPS Cyclohexylamino-1-propane sulfonic acid 
CrmA Cytokine responsive modifier A 
CAD Caspase-activated DNase 
CARD Caspase recruitment domain 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHOP C/EBP homologous protein 
CLSM Confocal laser scanning microscopy 
DED Death effector domain 
DEVD Asp-Glu-Val-Asp 
DFF DNA fragmentation factor 
DIABLO Direkt IAP binding protein with a low isoelectric point 
DISC Death inducing signalling complex 
DMSO Dimethyl sulfoxide 
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DNA Desoxyribonucleic acid 
DR Death receptor 
DTT Dithiothreitol 
ECL Enhanced chemoluminescence 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis(2-aminoethylether) tetraacetic acid 
EndoG Endonuclease G 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
FACS Fluorescence-activated cell sorter 
FADD Fas-associated death domain 
FCS Foetal calf serum 
FITC Fluorescein isothiocyanate 
FL-1 / FL-2 Fluorescence channel 1 / 2 
FSC Forward scatter 
GADD Growth arrest and DNA damage 
GI50 50 % growth inhibition 
h Hour 
HEPES N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HFS Hypotonic fluorochrome solution 
HPLC High performance liquid chromatography 
IAP Inhibitor of apoptosis protein 
IC50 Concentration required to achieve 50 % inhibition 
ICAD Inhibitor of caspase-activated DNase 
IMM Inner mitochondrial membrane 
IMS Intermembrane space 
JNK c-jun N-terminal kinase 
M phase Mitosis phase 
MIA Microtubuli-interfering agents 
mRNA Messenger RNA 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NCI National Cancer Institute 
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OMM Outer mitochondrial membrane 
PAA Polyacrylamide 
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate-buffered salime 
PI Propidium iodide 
PMSF Phenylmethanesulfonylfluoride 
PS Phosphatidylserine 
PTP Permeability transition pore 
PVDF Polyvinylidene fluoride 
QACXG Gln-Ala-Cys-X-Gly 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SCUBA Self-contained underwater breathing apparatus 
S phase Synthesis phase 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
SE Standard error 
Smac Second mitochondria-derived activator of caspases 
SSC Sideward scatter 
TBS-T Tris-buffered saline with Tween-20 
TEMED N, N, N’, N’ tetramethylethylene diamine 
TNF Tumour necrosis factor 
TRADD Trail-associated death domain 
TRAF2 TNF-receptor associated factor 2 
TRAIL TNF-receptor associated apoptosis inducing ligand 
UPR Unfolded protein response 
UV Ultraviolet 
VDAC Voltage-dependent anion channel 
XIAP X-linked inhibitor of apoptosis protein 
zLEHDfmk N-benzyloxycarbonyl-Leu-Glu(OMe)-His-Asp(OMe)-
fluoromethylketone 
zVADfmk N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone 
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2. ALPHABETICAL LIST OF COMPANIES 
Agfa  Köln, Germany 
Amersham Biosciences  Freiburg, Germany 
BD Pharmingen Heidelberg, Germany 
BD Transduction Laboratories Heidelberg, Germany 
Becton Dickinson Heidelberg, Germany 
Biometra Göttingen, Germany 
BioRad München, Germany 
Biozol Eching, Germany 
Calbiochem Schwalbach, Germany 
Cell Signaling Frankfurt, Germany 
Chemicon Hofheim, Germany 
Coulter Krefeld, Germany 
DakoCytomation GmbH Hamburg, Germany 
GraphPad Software, Inc. San Diego, USA 
Millipore Bedford, USA 
Molecular Probes Eugene, USA 
PAA Laboratories Cölbe, Germany 
PAN Biotech Aidenbach, Germany 
Roth Karlsruhe, Germany 
Sigma-Aldrich München, Germany 
SLT Labinstruments Crailsheim, Germany 
Tecan Crailsheim, Germany 
Trevigen Inc. Gaithersburg, MD, USA 
Upstate Lake Placid, USA 
Zeiss Munich, Germany 
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3. PUBLICATIONS 
3.1 ABSTRACTS 
I.M. Sönning, S.T. Eichhorst, G.R. Pettit, A.M. Vollmar, V.M. Dirsch 
Cephalostatin 1-induced apoptosis is characterized by selective mitochondrial 
release of Smac 
Naunyn-Schmiedeberg’s Archive of Pharmacology, Vol. 367, Suppl. 1 
 
I.M. Müller, G.R. Pettit, A.M. Vollmar, V.M. Dirsch 
Cephalostatin 1 induces Bcl-2 hyperphosphorylation without prior G2/M phase 
arrest 
Naunyn-Schmiedeberg’s Archive of Pharmacology, Vol. 369, Suppl. 1 
 
I.M. Müller, G.R. Pettit, A.M. Vollmar, V.M. Dirsch 
Cephalostatin 1 inaktiviert Bcl-2 unabhängig von einem M-Phasenarrest oder 
einer DNA-Schädigung 
Doktorandentagung der Deutschen Pharmazeutischen Gesellschaft 
Freudenstadt-Lauterbach, 2004 
3.2 ORIGINAL PUBLICATIONS 
V.M. Dirsch, I.M. Müller, S.T. Eichhorst, G.R. Pettit, Y. Kamano, M. Inoue, J-P. 
Xu, Y. Ichihara, G. Wanner, A.M. Vollmar 
Cephalostatin 1 selectively triggers the release of Smac/DIABLO and 
subsequent apoptosis that is characterized by an increased density of the 
mitochondrial matrix 
Cancer Res. 2003, 63, 8869-8876 
 
I.M. Müller, V.M. Dirsch, G.R. Pettit, A.M. Vollmar 
Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-
phase arrest and DNA damage 
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